| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2001;103:2994.)
© 2001 American Heart Association, Inc.
AHA Scientific Statement |
Guide to Anticoagulant Therapy: Heparin
A Statement for Healthcare Professionals From the American Heart Association
Key Words: AHA Scientific Statement • anticoagulants • heparin
 |
Introduction |
|---|
Top
Introduction
Clinical Consequences of...Thrombi are composed of fibrin and blood cells and may form in any part of the cardiovascular system, including veins, arteries, the heart, and the microcirculation. Because the relative proportion of cells and fibrin depends on hemodynamic factors, the proportions differ in arterial and venous thrombi.1 2 Arterial thrombi form under conditions of high flow and are composed mainly of platelet aggregates bound together by thin fibrin strands.3 4 5 In contrast, venous thrombi form in areas of stasis and are predominantly composed of red cells, with a large amount of interspersed fibrin and relatively few platelets. Thrombi that form in regions of slow to moderate flow are composed of a mixture of red cells, platelets, and fibrin and are known as mixed platelet-fibrin thrombi.4 5 When a platelet-rich arterial thrombus becomes occlusive, stasis occurs, and the thrombus can propagate as a red stasis thrombus. As thrombi age, they undergo progressive structural changes.6 Leukocytes are attracted by chemotactic factors released from aggregated platelets2 or proteolytic fragments of plasma proteins and become incorporated into the thrombi. The aggregated platelets swell and disintegrate and are gradually replaced by fibrin. Eventually, the fibrin clot is digested by fibrinolytic enzymes released from endothelial cells and leukocytes. The complications of thrombosis are caused either by the effects of local obstruction of the vessel, distant embolism of thrombotic material, or, less commonly, consumption of hemostatic elements.
Arterial thrombi usually form in regions of disturbed flow and at sites of rupture of an atherosclerotic plaque, which exposes the thrombogenic subendothelium to platelets and coagulation proteins; plaque rupture may also produce further narrowing due to hemorrhage into the plaque.7 8 9 10 11 Nonocclusive thrombi may become incorporated into the vessel wall and can accelerate the growth of atherosclerotic plaques.9 12 13 When flow is slow, the degree of stenosis is severe, or the thrombogenic stimulus is intense, the thrombi may become totally occlusive. Arterial thrombi usually occur in association with preexisting vascular disease, most commonly atherosclerosis; they produce clinical tissue ischemia either by obstructing flow or by embolism into the distal microcirculation. Activation both of blood coagulation and of platelets is important in the pathogenesis of arterial thrombosis. These 2 fundamental mechanisms of thrombogenesis are closely linked in vivo, because thrombin, a key clotting enzyme generated by blood coagulation, is a potent platelet activator, and activated platelets augment the coagulation process. Therefore, both anticoagulants and drugs that suppress platelet function are potentially effective in the prevention and treatment of arterial thrombosis, and evidence from results of clinical trials indicates that both classes of drugs are effective.
Venous thrombi usually occur in the lower limbs; although often silent, they can produce acute symptoms due to inflammation of the vessel wall, obstruction of flow, or embolism into the pulmonary circulation. They can produce long-term complications due to venous hypertension by damaging the venous valves. Activation of blood coagulation is the critical mechanism in pathogenesis of venous thromboembolism, whereas platelet activation is less important. Anticoagulants are therefore very effective for prevention and treatment of venous thromboembolism, and drugs that suppress platelet function are of less benefit.
Intracardiac thrombi usually form on inflamed or damaged valves, on endocardium adjacent to a region of myocardial infarction (MI), in a dilated or dyskinetic cardiac chamber, or on prosthetic valves. They are usually asymptomatic when confined to the heart but may produce complications due to embolism to the cerebral or systemic circulation. Activation of blood coagulation is more important in the pathogenesis of intracardiac thrombi than platelet activation, although the latter plays a contributory role. Anticoagulants are effective for prevention and treatment of intracardiac thrombi, and in patients with prosthetic heart valves, the efficacy of anticoagulants is augmented by drugs that suppress platelet function.
Widespread microvascular thrombosis is a complication of disseminated intravascular coagulation or generalized platelet aggregation. Microscopic thrombi can produce tissue ischemia, red cell fragmentation leading to a hemolytic anemia, or hemorrhage due to consumption of platelets and clotting factors. Anticoagulants are effective in selected cases of disseminated intravascular coagulation.
|
Clinical Consequences of Thrombosis |
|---|
It has been estimated that venous thromboembolism is responsible for more than 300 000 hospital admissions per year in the United States14 and that pulmonary embolism (PE) causes or contributes to death in
12% of hospitalized patients and is responsible for 50 000 to
250 000 deaths annually in the United States. The burden of illness
produced by venous thromboembolism includes death from PE (either acute
or, less commonly, chronic), long-term consequences of the
postthrombotic syndrome, the need for hospitalization, complications of
anticoagulant therapy, and the psychological impact of a potentially
chronic, recurrent illness. Arterial thrombosis is responsible for many of the acute manifestations of atherosclerosis and contributes to the progression of atherosclerosis. The burden of illness from atherosclerosis is enormous. As a generalized pathological process, atherosclerosis affects the arteries supplying blood to the heart, brain, and abdomen or legs, causing acute and chronic myocardial ischemia, including sudden death, MI, unstable angina, stable angina, ischemic cardiomyopathy, chronic arrhythmia, and ischemic cerebrovascular disease (including stroke, transient ischemic attacks, and multi-infarct dementia). In addition, atherosclerosis can cause renovascular hypertension, peripheral arterial disease with resulting intermittent claudication and gangrene, and bowel ischemia, and it can compound the complications of diabetes mellitus and hypertension. Thromboembolism that originates in the heart can cause embolic stroke and peripheral embolism in patients with atrial fibrillation (AF), acute MI, valvular heart disease, and cardiomyopathy.
The second version of "A Guide to Anticoagulant Therapy" was published in 1994. Since then, the following important advances have been made: (1) low-molecular-weight heparin (LMWH) preparations have become established anticoagulants for treatment of venous thrombosis and have shown promise for the treatment of patients with acute coronary syndromes; (2) direct thrombin inhibitors have been evaluated in venous thrombosis and acute coronary syndromes; (3) important new information has been published on the optimal dose/intensity for therapeutic anticoagulation with coumarin anticoagulants; and (4) the dosing of heparin for adjunctive therapy in patients with acute coronary syndromes has been reduced because conventional doses cause serious bleeding when combined with thrombolytic therapy or glycoprotein (GP) IIb/IIIa antagonists.
Whenever possible, the recommendations in this review of anticoagulant therapy are based on results of well-designed clinical trials. For some indications or clinical subgroups, however, recommendations are of necessity based on less solid evidence and are therefore subject to revision as new information emerges from future studies.
|
Historical Highlights |
|---|
Heparin was discovered by McLean in 1916.15 More than 20 years later, Brinkhous and associates16 demonstrated that heparin requires a plasma cofactor for its anticoagulant activity; this was named antithrombin III by Abildgaard in 196817 but is now referred to simply as antithrombin (AT). In the 1970s, Rosenberg, Lindahl, and others elucidated the mechanisms responsible for the heparin/AT interaction.18 19 20 It is now known that the active center serine of thrombin and other coagulation enzymes is inhibited by an arginine reactive center on the AT molecule and that heparin binds to lysine sites on AT, producing a conformational change at the arginine reactive center that converts AT from a slow, progressive thrombin inhibitor to a very rapid inhibitor.18 AT binds covalently to the active serine center of coagulation enzymes; heparin then dissociates from the ternary complex and can be reutilized18 (Figure 1
). Subsequently, it was
discovered18 19 20
that heparin binds to and potentiates the activity of AT through a
unique glucosamine
unit18 19 20 21
contained within a pentasaccharide
sequence,22 the structure of
which has been confirmed. A synthetic pentasaccharide has been
developed and is undergoing clinical evaluation for prevention and
treatment of venous
thrombosis.23 24
|
) and induces a conformational change in AT-III, thereby converting AT-III from a slow to a very rapid inhibitor. Bottom, AT-III binds covalently to the clotting enzyme, and the heparin dissociates from the complex and can be reused. Reprinted with permission from Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 suppl):64S–94S. |
Mechanism of Action of Heparin |
|---|
Only approximately one third of an administered dose of heparin binds to AT, and this fraction is responsible for most of its anticoagulant effect.25 26 The remaining two thirds has minimal anticoagulant activity at therapeutic concentrations, but at concentrations greater than those usually obtained clinically, both high- and low-affinity heparin catalyze the AT effect of a second plasma protein, heparin cofactor II27 (Table 1
).
|
The heparin-AT complex inactivates a number of
coagulation enzymes, including thrombin factor (IIa) and factors Xa,
IXa, XIa, and XIIa.18
Of these, thrombin and factor Xa are the most responsive to inhibition,
and human thrombin is 10-fold more sensitive to inhibition by the
heparin-AT complex than factor Xa
(Figure 2). For inhibition of thrombin, heparin must bind to
both the coagulation enzyme and AT, but binding to the enzyme is less
important for inhibition of activated factor X (factor Xa;
Figure 3).21
Molecules of heparin with fewer than 18 saccharides do not bind
simultaneously to thrombin and AT and therefore are unable
to catalyze thrombin inhibition. In contrast, very small heparin
fragments containing the high-affinity pentasaccharide sequence
catalyze inhibition of factor Xa by
AT.28 29 30 31
By inactivating thrombin, heparin not only prevents fibrin formation
but also inhibits thrombin-induced activation of factor V and factor
VIII.32 33 34
|
|
Heparin is heterogeneous with respect to
molecular size, anticoagulant activity, and pharmacokinetic properties
(Table 2). Its molecular weight ranges from 3000 to 30 000
Da, with a mean molecular weight of 15 000 Da (45
monosaccharide chains;
Figure 4).35 36 37
The anticoagulant activity of heparin is heterogeneous,
because only one third of heparin molecules administered to patients
have anticoagulant function, and the anticoagulant profile and
clearance of heparin are influenced by the chain length of the
molecules, with the higher-molecular-weight species cleared from the
circulation more rapidly than the lower-molecular-weight species. This
differential clearance results in accumulation of the
lower-molecular-weight species, which have a lower ratio of AT to
anti-factor Xa activity, in vivo. This effect is responsible for
differences in the relationship between plasma heparin concentration
(measured in anti-factor Xa units) and the activated partial
thromboplastin time (aPTT). The lower-molecular-weight species that are
retained in vivo are measured by the anti-factor Xa heparin assay, but
these have little effect on the aPTT.
|
|
In vitro, heparin binds to platelets and, depending on
the experimental conditions, can either induce or inhibit platelet
aggregation.38 39
High-molecular-weight heparin fractions with low affinity for AT have a
greater effect on platelet function than LMWH fractions with high
AT affinity40
(Table 1
). Heparin prolongs bleeding time in
humans41 and enhances blood
loss from the microvasculature in
rabbits.42 43 44
The interaction of heparin with
platelets42 and
endothelial
cells43 may contribute to
heparin-induced bleeding by a mechanism independent of its
anticoagulant
effect.44
In addition to anticoagulant effects, heparin increases vessel wall permeability,43 suppresses the proliferation of vascular smooth muscle cells,45 and suppresses osteoblast formation and activates osteoclasts, effects that promote bone loss.46 47 Of these 3 effects, only the osteopenic effect is relevant clinically, and all 3 are independent of the anticoagulant activity of heparin.48
|
Pharmacology of Unfractionated Heparin |
|---|
The 2 preferred routes of administration of unfractionated heparin (UFH) are continuous intravenous (IV) infusion and subcutaneous (SC) injection. When the SC route is selected, the initial dose must be sufficient to overcome the lower bioavailability associated with this route of administration.49 If an immediate anticoagulant effect is required, the initial dose should be accompanied by an IV bolus injection, because the anticoagulant effect of SC heparin is delayed for 1 to 2 hours.
After entering the bloodstream, heparin binds to a number of
plasma proteins
(Figure 5), which reduces its anticoagulant activity at low
concentrations, thereby contributing to the variability of the
anticoagulant response to heparin among patients with thromboembolic
disorders50 and to the
laboratory phenomenon of heparin
resistance.51 Heparin also
binds to endothelial
cells52 and
macrophages, properties that further complicate its
pharmacokinetics. Binding of heparin to von Willebrand factor
also inhibits von Willebrand factor–dependent platelet
function.53
|
). Only heparin with high-affinity pentasaccharide binds to AT-III, whereas binding to other proteins and to cells is nonspecific and occurs independently of the AT-III binding site. Reprinted with permission from Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 suppl):64S–94S.
Heparin is cleared through a combination of a rapid
saturable mechanism and much slower first-order
mechanisms54 55 56
(Figure 6). The saturable phase of heparin clearance is
attributed to binding to endothelial cell
receptors57 58
and macrophages,59
where it is
depolymerized60 61
(Figure 5). The slower, unsaturable mechanism of clearance is
largely renal. At therapeutic doses, a considerable proportion of
heparin is cleared through the rapid saturable, dose-dependent
mechanism
(Figure 6). These kinetics make the anticoagulant response to
heparin nonlinear at therapeutic doses, with both the intensity and
duration of effect rising disproportionately with increasing dose.
Thus, the apparent biological half-life of heparin increases from 30
minutes after an IV bolus of 25 U/kg to 60 minutes with an IV bolus of
100 U/kg and 150 minutes with a bolus of 400
U/kg.54 55 56
|
The plasma recovery of heparin is reduced62 when the drug is administered by SC injection in low doses (eg, 5000 U/12 h) or moderate doses of 12 500 U every 12 hours63 or 15 000 U every 12 hours.49 However, at high therapeutic doses (>35 000 U/24 hours), plasma recovery is almost complete.64 The difference between the bioavailability of heparin administered by SC or IV injection was demonstrated strikingly in a study of patients with venous thrombosis49 randomized to receive either 15 000 U of heparin every 12 hours by SC injection or 30 000 U by continuous IV infusion; both regimens were preceded by an IV bolus dose of 5000 U. Therapeutic heparin levels and aPTT ratios were achieved at 24 hours in only 37% of patients given SC heparin compared with 71% of those given the same total dose by continuous IV infusion.
|
Dose-Response Relationships and Laboratory Monitoring |
|---|
The risk of heparin-associated bleeding increases with dose65 66 and with concomitant thrombolytic67 68 69 70 or abciximab71 72 therapy. The risk of bleeding is also increased by recent surgery, trauma, invasive procedures, or concomitant hemostatic defects.73 Randomized trials show a relationship between the dose of heparin administered and both its efficacy49 63 74 and its safety.71 72 Because the anticoagulant response to heparin varies among patients with thromboembolic disorders,75 76 77 78 it is standard practice to adjust the dose of heparin and monitor its effect, usually by measurement of the aPTT. This test is sensitive to the inhibitory effects of heparin on thrombin, factor Xa, and factor IXa. Because there is a relationship between heparin dose and both anticoagulant effect and antithrombotic efficacy, it follows that there should be a relationship between anticoagulant effect and antithrombotic efficacy.
In the past, we were secure in the contention that a strong
relationship existed between the ex vivo effect of heparin on the aPTT
and its clinical effectiveness, but several lines of evidence have
challenged the strength of such a relationship. First, the initial
findings supporting a tight relationship between the effect of heparin
on aPTT and its clinical efficacy were based on retrospective subgroup
analysis of cohort studies and are therefore subject to
potential
bias49 63 75 76 77 78 79
(Table 3). Second, the results of a randomized
trial80 and 2 recent
meta-analyses of contemporary cohort
studies81 82 call
into question the value of the aPTT as a useful predictor of heparin
efficacy in patients with venous thrombosis. Third, no direct
relationship between aPTT and efficacy was observed in the subgroup
analysis of the GUSTO-I study (Global Utilization of
Streptokinase and Tissue plasminogen activator
for Occluded coronary arteries) in patients with acute MI who
were treated with thrombolytic therapy followed by
heparin.83 Fourth, even if
the aPTT results were predictive of clinical efficacy, the value of
this test would be limited by the fact that commercial aPTT reagents
vary considerably in responsiveness to
heparin.84 Although
standardization can be achieved by calibration against plasma heparin
concentration (the therapeutic range is 0.2 to 0.4 U/mL based on
protamine titration or 0.3 to 0.7 U/mL based on
anti-factor Xa chromogenic assay), this is beyond the scope
of many clinical laboratories. Heparin monitoring is likely to become
less problematic in the future as LMWH replaces UFH for
most
indications.85
|
Despite its limitations for monitoring heparin, aPTT remains
the most convenient and most frequently used method for monitoring the
anticoagulant response. aPTT should be measured 6 hours after the
bolus dose of heparin, and the continuous IV dose should be adjusted
according to the result. Various heparin dose-adjustment nomograms have
been developed86
(Tables 4 and 5), but none are
applicable to all aPTT
reagents,84 and the
therapeutic range must be adapted to the responsiveness of the reagent
used. In addition, the dosage regimen should be modified when heparin
is combined with thrombolytic
therapy87 or platelet GP
IIb/IIIa
antagonists.72
When heparin is given by SC injection in a dose of 35 000 U/24 hours
in 2 divided doses,64 the
anticoagulant effect is delayed 1 hour, and peak plasma levels occur
after 3 hours.
|
|
|
Limitations of Heparin |
|---|
The limitations of heparin are based on its pharmacokinetic, biophysical, and nonanticoagulant biological properties.88 All are caused by the AT-independent, charge-dependent binding properties of heparin to proteins and surfaces. Pharmacokinetic limitations are caused by AT-independent binding of heparin to plasma proteins,89 proteins released from platelets,90 and possibly endothelial cells, resulting in the variable anticoagulant response to heparin and the phenomenon of heparin resistance.80 AT-independent binding to macrophages and endothelial cells also results in a dose-dependent mechanism of heparin clearance.
The biophysical limitations occur because the heparin-AT complex is unable to inactivate factor Xa in the prothrombinase complex and thrombin bound to fibrin or to subendothelial surfaces. The biological limitations of heparin include osteopenia and heparin-induced thrombocytopenia (HIT). Osteopenia is caused as a result of binding of heparin to osteoblasts,46 which then release factors that activate osteoclasts, whereas HIT results from heparin binding to platelet factor 4 (PF4), forming an epitope to which the HIT antibody binds.91 92 The pharmacokinetic and nonanticoagulant biological limitations of heparin are less evident with LMWH,93 whereas the limited ability of the heparin-AT complex to inactivate fibrin-bound thrombin and factor Xa is overcome by several new classes of AT-independent thrombin and factor Xa inhibitors.94
Platelets, fibrin, vascular surfaces, and plasma proteins modify the anticoagulant effect of heparin. Platelets limit the anticoagulant effect of heparin by protecting surface factor Xa from inhibition by the heparin-AT complex95 96 and by secreting PF4, a heparin-neutralizing protein.97 Fibrin limits the anticoagulant effect of heparin by protecting fibrin-bound thrombin from inhibition by heparin AT.98 Heparin binds to fibrin and bridges between fibrin and the heparin binding site on thrombin. As a result, heparin increases the affinity of thrombin for fibrin, and by occupying the heparin binding site on thrombin, it protects fibrin-bound thrombin from inactivation by the heparin-AT complex.99 100 Thrombin also binds to subendothelial matrix proteins, where it is protected from inhibition by heparin.101 These observations explain why heparin is less effective than the AT-independent thrombin and factor Xa inhibitors94 for preventing thrombosis at sites of deep arterial injury in experimental animals102 103 and may explain why hirudin is more effective than heparin in patients with unstable angina or non–Q-wave MI.104
|
Clinical Use of Heparin |
|---|
Heparin is effective for the prevention and treatment of venous thrombosis and PE, for prevention of mural thrombosis after MI, and for treatment of patients with unstable angina and MI. Although heparin is used to prevent acute thrombosis after coronary thrombolysis, recent reports question the benefits of heparin in this setting when patients are also treated with aspirin (see below).
In patients with venous thromboembolism or unstable angina,
the dose of heparin is usually adjusted to maintain aPTT at an
intensity equivalent to a heparin level of 0.2 to 0.4 U/mL as measured
by protamine titration or an anti-factor Xa
level of 0.30 to 0.7 U/mL. For many aPTT reagents, this is equivalent
to a ratio (patient/control aPTT) of 1.5 to 2.5. The recommended
therapeutic
range49 79 is
based on evidence from animal
studies105 and supported by
subgroup analysis of prospective cohort studies involving
treatment of deep vein thrombosis
(DVT),49 prevention of mural
thrombosis after MI,63 and
prevention of recurrent ischemia after coronary
thrombolysis.75 76
Recommended heparin regimens for venous and arterial
thrombosis are summarized in
Table 6.
|
Treatment of Venous Thromboembolism
Use of heparin for the treatment of venous thrombosis
and PE is based on results of randomized
studies.106 107
The effectiveness and safety of heparin administered by continuous IV
infusion have been compared with intermittent IV injection in 6
studies108 109 110 111 112 113
and with high-dose SC heparin in 6
studies.64 114 115 116 117 118
It is difficult to determine the optimal route of heparin
administration because different doses were used in these studies, most
of the studies were small and underpowered, and different criteria were
used to assess efficacy and safety. Nevertheless, the results indicate
that heparin is safe and effective when appropriate doses are given.
Thus, in a recent pooled analysis of 11 clinical trials in
which 15 000 patients were treated with either heparin
(administered as an initial bolus of 5000 U followed by 30 000 to
35 000 U/24 hours with aPTT monitoring) or SC
LMWH,119 the mean incidence
of recurrent venous thromboembolism among patients assigned heparin was
5.4%. The rate of major bleeding was 1.9%, fatal recurrent venous
thromboembolism occurred in 0.7%, and bleeding was fatal in 0.2% of
heparin-treated patients. The initial dose of heparin is particularly
critical when heparin is administered by SC injection, because an
adequate anticoagulant response is not achieved in the first 24 hours
unless a high starting dose is used (17 500 U
SC).64
Audits of heparin monitoring practices indicate that dosage
adjustments are frequently inadequate, and dosing practices can be
improved by use of a simple and effective weight-adjusted dosage
regimen.74 There is evidence
that a 5-day course of heparin is as effective as a 10-day
course120 121
(Table 7). The short-course regimen has obvious appeal,
reducing hospital stay and the risk of HIT. Although the shorter course
of treatment can be recommended for most patients with venous
thromboembolism, this may not be appropriate in cases of extensive
iliofemoral vein thrombosis or major PE, because such patients were
underrepresented in these
studies.120 121
|
Prophylaxis of Venous Thromboembolism
Heparin in a fixed low dose of 5000 U SC every 8 or 12
hours is an effective and safe form of prophylaxis in medical and
surgical patients at risk of venous thromboembolism. Low-dose heparin
reduces the risk of venous thrombosis and fatal PE by 60% to
70%.122 123
Among general surgical patients, the incidence of fatal PE was reduced
from 0.7% in controls to 0.2% in one study
(P<0.001)120
and from 0.8% to 0.3%
(P<0.001) in a larger
analysis that included orthopedic surgical
patients.123 There was also
a small but statistically significant decrease in mortality from 3.3%
to 2.4% with low-dose heparin prophylaxis
(P<0.02).123
The use of low-dose heparin is associated with a small excess incidence
of wound
hematoma122 123 124
and a minimal, statistically insignificant increase in major bleeding
but no increase in fatal bleeding. Low-dose heparin also effectively
prevents venous thromboembolism in patients with MI and in those with
other serious medical
disorders,125 and it
reduced in-hospital mortality by 31%
(P<0.05) in a study of 1358
general medical patients aged >40
years.126 Although low-dose
heparin is also effective in reducing DVT after hip
surgery,123 the incidence
of thrombosis remains substantial (20% to 30%) and can be reduced
further with either adjusted low-dose
heparin127 or fixed-dose
LMWH.93 Moderate-dose
warfarin is effective in patients undergoing major orthopedic surgical
procedures,128 129
but direct comparisons of low-dose heparin and warfarin have not been
performed in major orthopedic surgery.
Coronary Artery Disease
Coronary thrombosis is important in the
pathogenesis of unstable angina, acute MI, and sudden cardiac death. It
is also important in the pathogenesis of reinfarction and death in
patients with acute MI treated with thrombolytic agents
or percutaneous transluminal coronary
angioplasty. In most patients, heparin ameliorates the thrombotic
manifestations of acute coronary syndromes, but it is no longer
used as the sole antithrombotic drug in these settings. Today, heparin
is always used in combination with aspirin in potentially eligible
patient groups with acute myocardial
ischemia,130 in
those receiving thrombolytic therapy for evolving MI,
in those treated with platelet GP IIb/IIIa antagonists
for unstable
angina,131 132
and in those undergoing high-risk coronary
angioplasty.71 72 132
When combined with
aspirin,130 133
thrombolytic agents, or GP IIb/IIIa
antagonists, however, heparin in full doses increases the
risk of bleeding, and the dose is usually reduced in these
settings.72
Unstable Angina and Non–Q-Wave MI
Heparin has been evaluated in a number of randomized,
double-blind, placebo-controlled clinical trials for the short-term
treatment of unstable angina or non–Q-wave
MI.134 135 136 137
When given alone to patients with unstable angina, heparin is effective
in preventing acute MI and recurrent
angina,135 136 137
and when used in combination with aspirin, the results of a
meta-analysis of 6 small trials suggest that the combination
also reduces short-term rates of cardiovascular death
and MI by 30% over those achieved with aspirin
alone.134
Theroux et al135
compared the relative efficacy and safety of heparin, aspirin, and
their combination in 479 patients with unstable angina. Heparin was
administered as an initial 5000-U IV bolus, followed by IV infusion of
1000 U/h, adjusted to maintain the aPTT at 1.5 to 2.0 times the control
value. Treatment was initiated within 24 hours after the onset of chest
pain and continued for 6 days. The incidence of MI during the acute
period was 11.9% in the placebo group and was reduced to 3.3% in the
aspirin groups
(P=0.012), 0.8% in the heparin
group (P<0.0001), and 1.6% in
the group given the combination of aspirin and heparin
(P=0.001). The incidence of
refractory angina (22.9% in the placebo group) was significantly
reduced to 8.5% (P=0.002) in
the heparin group and 10.7% in the heparin-plus-aspirin group
(P=0.11) but was 16.5% in the
aspirin group. In a second
study,138 these
investigators compared the efficacy and safety of heparin and aspirin.
This was a continuation of the previous study in which the placebo and
combination groups were discontinued and an additional 245 patients
were randomized to receive either continuous IV heparin or oral aspirin
twice daily during the in-hospital phase (6 days). Fatal or nonfatal
MI occurred during the acute period in 4 of 362 heparin-treated
patients compared with 23 of 362 patients who did not receive heparin
(odds ratio [OR] 0.16,
P<0.005).
In contrast, the RISC (Research group in InStability in Coronary artery disease) investigators134 did not show that heparin was more effective than aspirin. They compared low-dose aspirin (75 mg/d) with intermittent IV heparin (10 000 U bolus every 6 hours during the initial 24 hours followed by 7500 U every 6 hours for 5 days) in 796 men with unstable angina or non–Q-wave MI. Patients were randomized on the basis of a factorial design to treatment with heparin, aspirin, heparin plus aspirin, or placebo. The main outcome was a composite of MI or death evaluated 5 days after enrollment. The rate of this end point was 6.0% in the placebo group, 5.6% in the heparin group, 3.7% in the aspirin group, and 1.4% in the combined treatment group and was significantly reduced only with the combination (P=0.027). At 30 and 90 days, both the aspirin and aspirin-plus-heparin groups showed significantly better results than the placebo group, but the outcome with heparin alone was no better than with placebo.
Cohen et al139 performed a randomized, open-label study of 214 patients with unstable angina or non–Q-wave MI assigned to either aspirin (162.5 mg/d) or aspirin plus heparin for 3 to 4 days and warfarin for up to 12 weeks after enrollment. The main outcome measure was a composite of recurrent angina, MI, or death. After 12 weeks, the incidence of the main outcome was 28% for the aspirin group and 19% for the aspirin-plus-anticoagulation group (P=0.09).
A meta-analysis of published data from 6 small
randomized trials (n=1353 subjects), including the 3 described above,
reported a risk reduction of 33% (95% confidence interval [CI]
-2% to 56%) in cardiovascular death and MI with the
combination of UFH and aspirin, which was of borderline significance
(Figure 7).130
|
Acute MI
Information on the benefit of heparin in patients with
acute MI not given thrombolytic therapy is limited to
those who were not treated with aspirin either, so the results may not
be applicable to current clinical practice. An overview of randomized
clinical trials performed before the reperfusion era reported a 17%
reduction in mortality and a 22% reduction in reinfarction in patients
assigned heparin.140 The
control groups in these trials were not treated with aspirin, which is
now considered routine.
The effect of heparin on the incidence of mural thrombosis has been evaluated in 2 randomized trials.141 142 One compared heparin in a fixed dose of 12 500 U SC every 12 hours with an untreated control group, and the other used low-dose heparin (5000 U SC every 12 hours) for comparison. In both studies, moderate-dose heparin (12 500 U SC every 12 hours) reduced the incidence of mural thrombosis detected by 2-dimensional echocardiography by 72% and 58%, respectively (P<0.05 for each study).
Coronary
Thrombolysis
Although in the past it was generally accepted that
heparin was effective after coronary
thrombolysis, the results of recent studies cast doubt
on this view. In 3 studies that used angiographic patency as a usually
surrogate end point, the combination of heparin and aspirin was not
compared with aspirin alone. Topol et
al143 reported that a
single IV bolus of 10 000 U of heparin did not improve
coronary artery patency at 90 minutes. In another trial, in
which heparin alone was compared with no
treatment,144 patency of
the infarct-related artery at 2 days was 71% in the heparin group and
44% in the control group
(P<0.023). In the
Heparin-Aspirin Reperfusion
Trial,145 coronary
artery patency at 18 hours was 82% in patients treated with heparin
and 52% in a group given aspirin 80 mg/d
(P<0.0002). The conclusion
that heparin is more effective than aspirin in maintaining patency has
been criticized because the aspirin dose was too low to completely
suppress platelet thromboxane A2
production. The results were less impressive when the
combination of heparin and aspirin was compared with aspirin in a dose
of 325 mg/d. In the sixth European Cooperative Study Group (ECSG-6)
trial,77 687 patients
receiving aspirin were randomized to heparin or no heparin. Patency at
a mean of 81 hours was 80% in the heparin group and 75% in the
comparison group (P<0.01). In
the Australian National Heart Study
Trial,146 202 patients
received heparin for 24 hours before randomization to either continuous
IV heparin or a combination of aspirin (300 mg/d) and
dipyridamole (300 mg/d). Patency after 1 week was 80%
in both groups. Col et
al147 treated 128 patients
with streptokinase and aspirin and randomized the patients to either an
IV bolus of heparin or no heparin; the study reported no difference in
coronary patency at 24 hours (86% versus
87%).147 The DUCCS-1 (Duke
University Clinical Cardiology Studies) investigators
treated 250 patients with anisoylated
plasminogen–streptokinase activator complex
(APSAC) and aspirin and randomized patients to heparin or no heparin.
There was a small difference in coronary artery patency (80%
in the heparin group versus 74% in the control
group).148
Two large trials, the International Study Group149 and the ISIS-3150 (International Study of Infarct Survival) studies, assessed the value of adjunctive heparin in patients receiving thrombolytic therapy and aspirin. In both, heparin was given (12 500 U SC every 12 hours). In the International Study Group trial, heparin was begun 12 hours after randomization to fibrinolytic therapy; in the ISIS-3 trial, heparin began 4 hours after randomization.
The International Study Group study149 of 20 891 patients reported no difference in mortality between the heparin (8.5%) and no-heparin (8.9%) groups, whereas the risk of major bleeding was significantly increased by 0.5% in the heparin-treated group. The ISIS-3 study150 of 41 299 patients reported a vascular mortality rate of 10.3% in the heparin group and 10.0% in the no-heparin control group at 35 days. During the 7-day treatment period, mortality was 7.4% in the heparin group and 7.9% in the control group (P=0.06). In-hospital rates of reinfarction with heparin were 3.2% compared with 3.5% in the no-heparin group (P=0.09); stroke rates were not different. Major bleeding requiring transfusion was slightly more frequent in the heparin group (1.0% versus 0.8%, P<0.01).
In both studies, moderate doses of heparin produced marginal benefits at the cost of increased bleeding. The issue of whether IV heparin would prove more effective and at least as safe as the SC regimen used in the ISIS-3 study was addressed in the GUSTO trial,151 in which patients receiving streptokinase were given either a high-dose heparin regimen (5000 U initial IV bolus, followed by an infusion of 1000 to 1200 U/h to maintain aPTT at 60 to 85 seconds) or the delayed SC heparin regimen used in the ISIS-3 trial. IV heparin was not superior to SC heparin among patients receiving streptokinase either in terms of mortality, reinfarction, major hemorrhage, cerebral hemorrhage, infarct-related artery patency, or arterial reocclusion.
In a much smaller study, O’Connor et
al152 randomized 250
patients who had received APSAC to either aspirin alone or aspirin plus
weight-adjusted IV heparin beginning 4 hours after APSAC infusion.
There were no differences in ischemic outcomes, but bleeding
was significantly greater with heparin (32% versus 17.2%;
P=0.006). From a
meta-analysis composed largely of the International Study Group
and ISIS-3 studies, Collins and
associates133 reported that
in the presence of aspirin, heparin produced a relative risk reduction
of mortality of only 6% (95% CI 0% to 10%;
P=0.03),
representing just 5 fewer deaths per 1000 patients treated
(Table 8). There were 3 fewer reinfarctions per 1000
(P=0.04) and 1 fewer PE per
1000 patients (P=0.01). This
small beneficial effect was associated with an insignificant excess
incidence of stroke but a definite excess of 3 major bleeding incidents
per 1000 patients (P<0.0001).
In trials using high-dose heparin, there was an 2-fold increase in
the absolute risk of major extracranial bleeding (31 per 1322 [2.3%]
versus 14 per 1321 [1.1%];
P=0.01).153
|
Data on the role of adjunctive heparin in patients treated with tissue plasminogen activator are limited. From contemporary studies, Kruse and associates154 concluded that the role of heparin as adjunctive treatment to accelerated tissue plasminogen activator is still an open issue. A pooled analysis by Mahaffey et al155 of 6 randomized trials exposed a trend toward reduced in-hospital mortality with heparin (9% reduction; OR 0.91, 95% CI 0.59 to 1.39) but a significantly higher rate of hemorrhagic complications when adjunctive heparin was used in tissue plasminogen activator–treated patients.156
Recommendations for use of heparin in patients with acute MI are provided in the American College of Cardiology/American Heart Association guidelines.87 156 The intensity of the suggested heparin regimen is influenced by whether thrombolytic therapy is given, the type of thrombolytic agent used, and the presence or absence of risk factors for systemic embolism.
Coronary Angioplasty
Percutaneous transluminal
coronary angioplasty can be complicated by early thrombotic
occlusion in the instrumented artery. It is standard practice to give
heparin, commencing with either an IV bolus of 10 000 U with repeated
smaller bolus injections as required or as a weight-adjusted-dose
regimen of 100 to 175 U/kg followed by 10 to 15 U/kg per hour. The dose
is adjusted to maintain the activated clotting time (ACT)
greater than 300 to 350 seconds, because there is some evidence that
the complication rate is higher with lower ACT
values.157 When these
high-dose regimens are used in combination with abciximab and aspirin,
however, heparin increases the risk of major
bleeding.77 78
The risk can be reduced without compromising efficacy by lowering the
bolus dose of heparin to 70 U/kg and giving bolus doses as needed to
achieve an ACT of >200 seconds and by removing arterial
sheaths when the ACT falls below 150 to 180
seconds.78 After
coronary angioplasty, postprocedural heparin infusions are not
needed for most patients who are treated with a combination of aspirin
and ticlopidine.
A beneficial role for heparin has not been established when unstable angina develops within the first 6 months after coronary angioplasty. In a recent randomized trial, 200 patients who had undergone angioplasty without intracoronary stenting were randomized to IV nitroglycerin, heparin, the combination of both agents, or placebo for 63±30 hours. Recurrent angina developed in 75% of patients in the placebo and heparin-alone groups compared with 42.6% of patients in the nitroglycerin-alone group and 42% of patients in the nitroglycerin-plus-heparin group (P<0.003). Refractory angina occurred in 23%, 29%, 4%, and 4% of patients, respectively (P<0.002). The OR for being event free was 0.98 (95% CI -0.55 to 1.73, P=NS) for heparin versus no heparin in this study.158
Atrial Fibrillation
The role of heparin for prevention of ischemic
stroke and systemic embolism in high-risk patients with
nonvalvular AF has been less thoroughly investigated than oral
anticoagulation with warfarin. It is likely that heparin
represents an effective alternative to warfarin for
antithrombotic prophylaxis, because both anticoagulants decrease
hemostatic activation associated with atrial stasis in patients with
this cardiac rhythm
disturbance.159
Heparin is sometimes given as an alternative to oral anticoagulation
perioperatively in patients with chronic AF who are
undergoing elective surgery, but no consensus has emerged regarding
when and how to substitute heparin in this
situation.160
Patients with AF who have sustained recent cerebral
ischemic events are among those at highest risk of
thromboembolism (12% per year). Oral anticoagulation reduces the
risk by two thirds, similar to the benefit achieved in primary
prevention. When oral anticoagulation is contraindicated, aspirin is a
much less effective
alternative.161 How rapidly
and intensively to initiate anticoagulation after a cerebral
ischemic event is controversial, however, considering that
hemorrhagic transformation might worsen the neurological
deficit.162 163
In a study of 231 patients with nonvalvular AF and acute stroke, heparin was administered IV or SC in doses adjusted to an aPTT 1.5 to 2.0 times control values.164 Delay before the initiation of heparin therapy was <6 hours from the onset of symptoms in 74 patients and 6 to 48 hours in 157 patients. In-hospital mortality was 9%, hemorrhagic worsening occurred in 3% of patients, and stroke recurred early in 2% of patients. Neurological recovery was associated with age younger than 70 years (OR 0.2), normal baseline computed tomography (CT)-scan findings (OR 8.9), and early heparin treatment (OR 1.7, 95% CI 1.1 to 2.5), even though targeted aPTT ratios were achieved at 24 hours in fewer than 50% of patients. Stroke recurrence was associated with lower mean aPTT ratios, but higher ratios were observed in patients with symptomatic bleeding, especially on the day bleeding occurred. Neither age, initial stroke severity, blood pressure, or baseline CT findings predicted hemorrhagic worsening. Functional recovery was improved sooner when heparin was administered early, but close monitoring of aPTT was necessary to lessen the risk of hemorrhagic complications.
Hemorrhagic transformation after acute ischemic stroke is compounded by thrombolytic therapy, but the impact of heparin can only be inferred. The Multicenter Acute Stroke Trial-Europe (MAST-E) study165 evaluated the safety and efficacy of streptokinase administered IV within 6 hours of stroke onset. Among 310 patients, 159 (51%) had evidence of hemorrhagic transformation on CT scan, but only 23% of these were symptomatic. The relative risk of hemorrhagic transformation after streptokinase in this trial was in the same range as in other trials of thrombolytic therapy for acute stroke. Multivariate secondary analysis found that patients with symptomatic hemorrhagic transformation were more likely to have AF and less likely to have received heparin treatment.165
To minimize the risk of thromboembolism after electrical cardioversion of AF or flutter, therapeutic anticoagulation should be established for at least 3 weeks before and for 4 weeks after cardioversion when the dysrhythmia has persisted longer than 2 days or when the duration is unknown. Warfarin is usually used during the outpatient phase.166 167 A more recent approach uses transesophageal echocardiography to demonstrate the absence of thrombi in the left atrium and left atrial appendage. If no thrombus is evident, heparin anticoagulation may be initiated before pharmacological or electrical cardioversion, followed by warfarin therapy for 1 month after cardioversion. This treatment algorithm has a safety profile similar to that of conventional therapy and minimizes both the period of anticoagulation and the duration of AF before cardioversion, but no outcome superiority has been established.168
A similar rationale underlies the use of heparin in conjunction with radiofrequency catheter ablation of cardiac tachyarrhythmias. A review of the literature over the last 10 years found an overall incidence of reported thromboembolic complications of 0.6% associated with radiofrequency catheter ablation. The risk is increased (to 1.8% to 2%) when ablation is performed in the left heart, but this increase is less than when the indication is ventricular tachycardia (2.8%).169 For the ablation of AF, creation of extensive left atrial lesions has been associated with a high rate of thromboembolic stroke, despite administration of IV heparin and modulated electromagnetic energy. Adjuvant platelet inhibitor therapy to reduce the risk of thromboembolism in this specialized situation is under investigation.170
|
Heparin-Induced Thrombocytopenia |
|---|
HIT is an antibody-mediated adverse reaction to heparin that can result in venous or arterial thrombosis. Diagnosis of HIT is based on both clinical and serological features.171 172 Manifestations of the HIT syndrome include an otherwise unexplained fall in platelet count
50%, even if the nadir remains above
150x109/L, or skin lesions at heparin
injection
sites173 174
accompanied by HIT antibody formation. The fall in platelet count
almost always occurs between day 5 and day 15 after introduction of
heparin but can develop earlier in patients exposed to heparin during
the previous 3 months. The frequency of HIT varies in different
clinical
settings175 176
such that the risk of venous thrombosis from HIT is higher in high-risk
surgical patients175 than
in medical
patients.176
The HIT antigen is a multimolecular complex between PF4 and
heparin.91 92 177 178 179
HIT antibodies bind to regions of the PF4 molecule that have been
conformationally modified by its interaction with heparin. The
increased propensity to thrombosis in HIT is probably mediated by
thrombin generated as a result of in vivo platelet
activation,180 181
as a consequence of interaction between heparin/PF4/IgG immune
complexes with Fc receptors on
platelets.182 A minimum
of 12 to 14 saccharides are required to form the antigenic
complex with
PF4,178 179 so
heparin molecules with a molecular weight greater than 4000 Da have
the potential to cause HIT, and HIT occurs less commonly with LMWH than
with
UFH.183 184
Diagnosis
Two main classes of laboratory assays have been
developed to detect HIT
antibodies,185 186
activation assays and antigen assays. The use of washed platelets
rather than platelet-rich plasma derived from normal donors
increases the reliability of activation assays. Of the various
activation assays available, those that use washed platelets and
platelet serotonin
release187 or
heparin-induced platelet
activation188 189
are most accurate.173
Antigen assays, now commercially available, that are based on detecting
antibodies against PF4 bound to
heparin188 or
polyvinylsulfonate190
respond to clinically insignificant antibodies more often than do
activation
assays.175
Treatment
If HIT is suspected on clinical grounds and the patient
either has thrombosis or is at risk of developing thrombosis, heparin
should be stopped and replaced with lepirudin
(Refludan). Although the diagnosis should be
confirmed as soon as practical, treatment should not be delayed.
Warfarin should not be used alone, because a recent report suggests
this can aggravate the thrombotic process. Lepirudin is a
hirudin derivative that does not exhibit
cross-reactivity and is manufactured by recombinant
technology.191 Its use in
HIT has been approved by the Food and Drug Administration on the basis
of 2 prospective cohort
studies192 193
that compared treatment of HIT-associated thrombosis with lepirudin
versus historical controls. An IV infusion is used for rapid
therapeutic anticoagulation, beginning with a bolus loading dose of 0.4
mg/kg IV followed by a maintenance dose of 15 mg ·
kg-1 · h-1,
with adjustments to maintain aPTT at 1.5 to 2.5 times the median of the
normal laboratory range.
In the absence of overt thrombosis, cessation of heparin has
long been the cornerstone of management of HIT, but several studies
have shown that simply stopping heparin may be inadequate because of
the high risk of overt thrombosis in the week after interruption of
heparin.192 193 194 195 196 197
Treatment with hirudin should therefore be
considered in all patients with HIT who remain at risk of thrombosis,
including postoperative patients and those with sepsis. Recombinant
hirudin (lepirudin) should be used until the
platelet count has recovered
(Table 9). This should also be considered for patients with
acute HIT without thrombosis (isolated HIT), because there is a high
risk for subsequent clinically evident thrombosis in these patients.
Warfarin should not be used alone to treat acute HIT complicated by DVT
because of the risk of venous limb gangrene. When given to patients
adequately anticoagulated with lepirudin, warfarin appears safe in
acute HIT, but it is prudent to delay starting warfarin until the
platelet count has risen above
100x109/L.
|
|
Low-Molecular-Weight Heparins |
|---|
Historical Perspective
The development of LMWHs for clinical use was stimulated by 3 main observations. These are that compared with UFH, LMWH has reduced anti-factor IIa activity relative to anti-factor Xa activity,26 198 more favorable benefit-risk ratios199 200 201 202 203 204 in experimental animals, and superior pharmacokinetic properties.205 206 207 208 209 210 Of these potential advantages, only the pharmacokinetic properties are of clear clinical importance.93 211
LMWH fractions prepared from standard commercial-grade
heparin have progressively less effect on the aPTT as they are reduced
in molecular size, while still inhibiting activated factor X
(factor
Xa).26 198 The
aPTT activity of heparin reflects mainly its anti-factor IIa activity.
The disassociation of anti-factor Xa activity from AT (IIa) activity
(expressed as an aPTT measurement), described in
1976,26
challenged the prevailing biophysical model for the anticoagulant
effect of heparin, which predicted that any heparin molecule,
irrespective of chain length, would catalyze the inactivation of serine
protease coagulation enzymes equally provided it contained the
high-affinity binding site for AT. The explanation for the difference
in anticoagulant profile between LMWH and heparin was elucidated in
subsequent studies
(Table 10).29 30 212 213 214 215 216
|
Bleeding in Experimental Animals
Early evidence that LMWH produces less microvascular
bleeding than heparin in experimental
models199 200 201 202 203 204
has not been borne out by recent large randomized trials in the
prevention and treatment of venous thrombosis, treatment of PE, or
treatment of unstable angina. In these studies, LMWH and heparin have
shown similar low rates of bleeding (see below).
Pharmacokinetic Properties
In the 1980s, a number of
investigators205 206 207 208 209 210
reported that LMWH preparations had a longer plasma half-life and
better bioavailability at low doses than heparin, as well as a more
predictable dose
response.217 These findings
provided the rationale for comparing unmonitored weight-adjusted LMWH
with aPTT-monitored heparin in patients with established DVT and in
patients with unstable angina.
Structure and Pharmacology
LMWHs are derived from heparin by chemical or enzymatic
depolymerization to yield fragments approximately
one third the size of heparin. The various LMWHs approved for use in
Europe, Canada, and the United States are shown in
Table 11. Because they are prepared by different methods of
depolymerization, they differ to some extent in
pharmacokinetic properties and anticoagulant profile and are not
clinically interchangeable. LMWHs have a mean molecular weight of 4500
to 5000 Da with a distribution of 1000 to 10 000 Da.
|
Depolymerization of heparin yields
low-molecular-weight fragments with reduced binding to proteins or
cells
(Table 12). Indeed, all of the anticoagulant,
pharmacokinetic, and other biological differences between UFH and LMWH
can be explained by the relatively lower binding properties of LMWH.
Thus, compared with UFH, LMWHs have reduced ability to
inactivate thrombin because the smaller fragments cannot
bind simultaneously to AT and thrombin. On the other
hand, because bridging between AT and factor Xa is less critical
for anti-factor Xa activity, the smaller fragments
inactivatefactor Xa almost as well as larger
molecules.35 218 219 220
Reduced binding to plasma proteins is responsible for the more
predictable dose-response relationship of
LMWHs.89 Less binding to
macrophages and endothelial cells increases the
plasma half-life211 of LMWH
compared with UFH, whereas reduced binding to platelets and PF4 may
explain the lower incidence of
HIT.40 90 183
Finally, reduced binding of LMWH to osteoblasts results in less
activation of osteoclasts and less bone
loss.46 47 LMWHs
are cleared principally by the renal route, and their biological
half-life is prolonged in patients with renal
failure.221 222 223
|
Anticoagulant Effects
Like UFH, LMWHs produce their major anticoagulant
effect by activating AT. The interaction with AT is mediated by a
unique pentasaccharide
sequence21 224
found on fewer than one third of LMWH molecules. Because a minimum
chain length of 18 saccharides (including the
pentasaccharide sequence) is required for the formation of
ternary complexes between heparin chains, AT, and thrombin, only the
25% to 50% of LMWH species that are above this critical chain length
are able to inactivate thrombin. In contrast, all LMWH
chains containing the high-affinity pentasaccharide catalyze
the inactivation of factor Xa
(Figure 3). Because virtually all heparin molecules contain
at least 18 saccharide
units,213 214
heparin has an anti-factor Xa to anti-factor IIa ratio of 1:1. In
contrast, commercial LMWHs have anti-factor Xa to anti-IIa ratios
between 2:1 and 4:1, depending on their molecular size
distribution.
LMWHs have been evaluated in a large number of randomized clinical trials and have been found to be safe and effective for prevention and treatment of venous thrombosis. More recently, LMWH preparations have also been evaluated in patients with acute PE and those with unstable angina.
Prevention of Venous Thrombosis
LMWHs were first evaluated for the prevention of venous
thrombosis in high-risk surgical patients in the mid-1980s, and there
is now extensive experience with their use for this indication. In
patients undergoing general surgery and in high-risk medical patients,
low doses of LMWH administered SC once daily are at least as effective
and safe as low-dose UFH administered SC 2 or 3 times daily. LMWH has
become the anticoagulant of choice for the prevention of venous
thrombosis during major orthopedic surgery and in
anticoagulant-eligible patients after major trauma. The risk of
bleeding with LMWH is small and comparable to that with low-dose
heparin.
General Surgery
LMWHs were effective and safe in 2 well-designed
randomized trials. One
trial225 in 4498 patients
showed a statistically significant reduction in thromboembolic
mortality in favor of LMWH (0.07%) compared with a UFH control group
(0.36%). A
meta-analysis226 of
randomized trials comparing low-dose heparin with LMWH concluded that
there were minimal differences between the 2 forms of
prophylaxis.
Orthopedic Surgery
Compared with placebo, LMWH produced a risk reduction
for all thrombi and for proximal vein thrombi between 70% and 79%.
This reduction occurred without an increase in major bleeding in 2
studies227 228
and with a small increase in minor bleeding in a
third,229 but all were too
small to exclude a modest increase in major bleeding with LMWH. LMWH
has been compared with a variety of other methods of prophylaxis,
including low-dose
heparin,230 231 232
adjusted-dose
heparin,233 234
dextran,235 236
and warfarin.237 In most
studies performed in North America, the LMWH was started 12 to 24 hours
postoperatively, increasing the acceptance of prophylaxis among
orthopedic surgeons and anesthesiologists concerned about the risk of
spinal cord hematoma with prophylactic LMWH in patients
undergoing spinal anesthesia. In such cases, the first dose
of LMWH should be delayed until after the epidural catheter has been
removed; when this is not feasible, the catheter should be removed at
least 8 hours after the last dose of LMWH. In addition, other drugs
that impair hemostasis (such as nonsteroidal anti-inflammatory agents)
should be avoided.
Anderson et
al238 performed a
meta-analysis of randomized studies comparing LMWH with either
fixed low-dose or adjusted-dose heparin. The observed incidence of
venous thrombosis was 15.9% in the LMWH group and 21.7% in the
heparin group (P=0.01), and
there was a significant reduction in the incidence of proximal venous
thrombosis in the LMWH group (5.4% versus 12.5%;
P<0.0001). There was no
difference in the incidence of bleeding between the 2 groups
(Table 13). These results are comparable to those of an
earlier
meta-analysis.226
|
Two studies compared LMWH and low-dose heparin for prevention of venous thrombosis after elective total knee arthroplasty. In one, LMWH was more effective than heparin239 ; the incidence of venous thrombosis was 24.6% in the LMWH group and 34.2% in the heparin group (P=0.02). In the other,240 the incidence of venous thrombosis was 23% in the LMWH group and 27% in the heparin group. There was no difference in the incidence of bleeding in either study.
LMWH preparations have been compared with warfarin and other
oral anticoagulants in 6 studies involving high-risk orthopedic
surgical
patients.241 242 243 244 245 246
The LMWH preparations tested showed efficacy equal to warfarin in
patients undergoing elective hip replacement, but LMWHs appeared more
effective than oral anticoagulants in patients undergoing major knee
surgery
(Table 14). In a number of these studies, LMWH was
associated with a small but significant increase in major
bleeding.
|
Hip Fracture
Two randomized trials have been performed with
danaparoid sodium in patients with hip fracture. In
one,204 the incidence of
thrombosis was 13% in patients given danaparoid sodium
(Orgaran) and 35% in patients given dextran
(P<0.001). Blood transfusion
requirements were significantly higher in the dextran group. In the
other,247 venous thrombosis
occurred in 27.8% of the patients treated with danaparoid sodium and
in 44.8% of patients in the aspirin group
(P=0.028). There was no
difference in bleeding between the 2 groups.
Multiple Trauma
Geerts and
colleagues248 compared LMWH
(enoxaparin sodium [Lovenox/Clexane]; 30 mg SC
every 12 hours) with low-dose heparin (5000 U SC every 12 hours),
started within 36 hours of injury in victims of multiple trauma. The
incidence of venous thrombosis was 44% in the 136 patients allocated
to the low-dose heparin group and 31% among 129 patients in the LMWH
group (P=0.014). The incidence
of proximal venous thrombosis was 15% in the low-dose heparin group
and 6% in the LMWH group
(P=0.09).249
Major bleeding occurred in 0.6% of patients treated with heparin and
2.9% of those treated with LMWH.
Summary of LMWH in Orthopedic Surgery and
Trauma
Overall, LMWHs appear effective for prevention of
venous thromboembolism, and they appear safe for use in high-risk
patients undergoing major orthopedic surgical procedures. Compared with
placebo, the relative risk reduction for all thrombi and for proximal
vein thrombi is 70%. LMWHs are more effective than low-dose
heparin, at least as effective as warfarin, and more effective than
dextran or aspirin in patients undergoing total hip arthroplasty, and
they are more effective than warfarin, aspirin, or dextran in patients
undergoing major knee surgery. Similarly, LMWHs are more effective than
aspirin in patients with hip fracture. The risk of bleeding with LMWH
is comparable to that with low-dose heparin or
warfarin.
Neurosurgery
In a recent
study250 comparing LMWH
plus compression stockings with compression stockings alone, those
assigned to the LMWH group had a risk reduction of 48%. There was no
difference in major bleeding.
Medical Patients
LMWHs have been compared with placebo in 2 studies of
patients with ischemic
stroke251 252
and have been compared with low-dose heparin in 2
studies.253 254
Compared with placebo, LMWHs reduce the risk of venous thrombosis
between 40% and 86% without an increase in clinically important
bleeding. In studies comparing LMWHs with heparin, patients randomized
to receive LMWH showed a statistically significant >70% relative risk
reduction in
thrombosis.118,259
Treatment of Venous Thromboembolism
A number of LMWH preparations have been compared with
heparin in patients with venous thrombosis and/or PE in well-designed
studies. The results of studies published before 1995 that used 4
different preparations have been summarized in a
meta-analysis255 in
which the data for each of the 4 LMWHs were pooled separately
(Tables 15 and 16).
All 4 LMWH preparations were as effective and safe as IV heparin, and
the rates of recurrent thromboembolism and major bleeding were similar
with all of the LMWHs. It is noteworthy that the LMWHs were
administered by SC injection in unmonitored, weight-adjusted doses,
whereas heparin was monitored by the aPTT.
|
|
Since publication of the pooled analysis in
1995, 5 additional large randomized trials have been
completed,256 257 258 259 260
2 in patients with venous
thrombosis,257 258
1 in patients with venous thrombosis or
PE,259 1 in patients with
PE,256 and 1 in patients
with proximal vein thrombosis who were also randomized to
inferior vena cava filter
insertion.260 The design of
2 of the
studies257 258
capitalized on the more predictable anticoagulant response to LMWH by
encouraging patients assigned to LMWH treatment at home,
whereas those assigned to heparin were treated conventionally in the
hospital with a continuous IV infusion. The results, shown in
Table 17, indicate that out-of-hospital administration of
LMWH to eligible patients with DVT is as effective and safe as IV
heparin administered in the hospital. Both studies excluded patients
with symptomatic PE or a history of recent previous venous
thrombosis. To address this study deficiency, the investigators
collaborated in the COLUMBUS
study,259 in which 1021
patients with venous thrombosis or PE were randomly assigned to
treatment with either SC LMWH (riviparin sodium) or adjusted-dose IV
UFH for 8 days. Warfarin was started concomitantly and continued for 3
months. The mean hospital stay was 3 days shorter in patients assigned
to LMWH, whereas the incidence of recurrent thromboembolism, bleeding,
and mortality was similar in both groups.
|
The relative efficacy and safety of LMWH and heparin for
treatment of patients with acute PE have also been investigated in a
larger population. Patients who did not require
thrombolytic therapy or pulmonary embolectomy
(n=612) were randomly assigned to receive LMWH (tinzaparin, 175
anti-factor Xa U/kg SC once daily) or heparin (50 U/kg bolus followed
by a continuous infusion of 500 U · kg-1
· d-1 adjusted to an aPTT ratio of 2.0
to 3.0). The outcome measure, a composite of recurrent thromboembolism,
major bleeding, and death, was assessed on days 8 and 90. By day 8, 9
(2.9%) of 308 patients assigned to UFH and 9 (3.0%) of 304 patients
assigned to LMWH developed at least 1 of the primary events; by day 90,
22 patients (7.1%) assigned to UFH and 18 (5.9%) assigned to LMWH
developed events (P=0.54;
Table 18). The rate of major bleeding was similar in both
groups (2.6% and 2.0%, respectively;
P=NS). There were 3 deaths at 8
days and 14 deaths (4.5%) at 90 days in those assigned to UFH, and
there were 4 deaths at 8 days and 12 (3.9%) at 90 days in patients
assigned to LMWH. Five of the deaths in the heparin group were
treatment related (3 from PE and 2 from major bleeding) compared with 4
in the LMWH group (3 from PE and 1 from bleeding). The findings of this
study combined with those of the COLUMBUS study indicate that SC
weight-adjusted LMWH is as effective and safe as IV
heparin.
|
A
meta-analysis119 of
11 randomized studies comparing IV heparin and SC LMWH in 3500
patients with acute DVT
(Table 19) found major bleeding to be less frequent in
patients treated with LMWH (OR 0.57;
P=0.05). The frequency of
recurrent thromboembolic events did not differ significantly between
treatment groups (OR 0.85;
P=0.28), but the mortality rate
was lower in those assigned LMWH (OR 0.71;
P=0.02). Most of the deaths
were not ascribed to PE, so the mechanism for this mortality reduction
is uncertain.
|
Most studies evaluating LMWH preparations for treatment of venous thromboembolism evaluated a twice-daily, weight-adjusted regimen. However, 2 studies using tinzaparin, 1 in patients with acute venous thrombosis261 and the other in patients with acute PE,256 used once-daily dosing (175 anti-factor Xa U/kg). Results of comparisons of the efficacy and safety of LMWH administered once or twice daily262 263 found once-daily administration of 2 different LMWH preparations as effective and safe as twice-daily dosing.
Unstable Angina and Non–Q-Wave MI
Although the combination of heparin and aspirin is
effective for short-term treatment of patients with unstable angina,
between 6% and 15% progress to MI or death within 1 month despite
continuing aspirin
therapy.67 264
The recent success of LMWH for the treatment of venous thromboembolism
and the feasibility and safety of out-of-hospital use have led to the
evaluation of LMWH preparations administered SC without laboratory
monitoring in the setting of unstable angina and non–Q-wave MI. To
date, 7 randomized trials evaluating LMWH in patients with unstable
angina and non–Q-wave MI have been reported
(Table 20). Short- and long-term relative risk reductions
compared with UFH are shown in
Figures 8 and 9. The first small
trial265 (n=219) compared
nadroparin plus aspirin versus UFH plus aspirin versus aspirin alone
using an open-label design. The rate of acute MI, recurrent angina, and
urgent coronary revascularization was
significantly lower with the LMWH and aspirin combination than with UFH
and aspirin or aspirin alone. Subsequent to this, a large,
double-blind, placebo-controlled trial in 1506 patients with unstable
angina or non–Q-wave MI (FRISC; FRagmin during InStability in
Coronary artery
disease)266 compared 120
U/kg of dalteparin twice daily for 6 days followed by 7500 anti-factor
Xa U once daily for 35 to 45 days with placebo; all patients received
aspirin. Compared with placebo, LMWH reduced the risk of death or MI by
80% at 6 days. In addition, the composite end point of death, MI,
and need for revascularization was significantly
lower in patients treated with LMWH (10.3% versus 5.4%). However, no
additional benefit was observed with long-term lower-dose LMWH (7500
anti-factor Xa U of dalteparin once daily) compared with placebo. After
4 to 5 months of follow-up, the rates of death and MI in the placebo
and dalteparin groups was 15.3% and 14.0%, respectively
(P=0.41), and the rates of
death, MI, or revascularization were 43.6% and
42.7%, respectively (P=0.18).
This study established the short-term value of LMWH (dalteparin) for
treatment of unstable angina and non–Q-wave MI and added to the data
in support of a beneficial effect of heparin and aspirin over aspirin
alone in this patient population. However, no effect of moderate-dose
LMWH was observed over the long term.
|
|
|
In a third study (FRIC; FRagmin In unstable Coronary artery disease),267 which used an open, randomized design, dalteparin (120 anti-factor Xa U/kg twice daily) was compared with heparin (5000-U bolus followed by 1000-U/h continuous infusion for 6 days) in 1492 patients with unstable angina or non–Q-wave infarction. This was followed in a second phase by a double-blind study comparing LMWH at a dose of 7500 U/d with placebo. All patients received aspirin. Both treatment regimens were equivalent in terms of efficacy and safety. At 6 days, the composite outcome of death, MI, or recurrent angina occurred in 7.6% of the heparin group and 9.3% of the LMWH group, whereas the corresponding rates of the composite of death or MI were 3.6% and 3.9%, respectively. Between days 6 and 45, the rate of death, MI, or recurrent angina was 12.3% in both groups. There was no difference in major bleeding, which was infrequent.
The ESSENCE trial (Efficacy and Safety of Subcutaneous
Enoxaparin in Non-Q-wave Coronary
Events)268 is 1 of 2
studies that compared enoxaparin with heparin. Patients (n=3171) with
unstable angina or non–Q-wave MI were randomized in a double-blind
fashion to 1 mg/kg SC (100 anti-factor Xa U) of enoxaparin every 12
hours or UFH, administered as an IV bolus followed by a continuous
infusion, for 2 to 8 days; the median duration of treatment in both
groups was 2.6 days
(Table 20). There was a significant 17% risk reduction in
the primary end point of death, MI, or recurrent angina at 14 days with
LMWH (P=0.019) and a 15% risk
reduction at 30 days (P=0.016).
This difference was accounted for mainly by a lower incidence of
recurrent angina in patients assigned to LMWH. There was no difference
in the incidence of major bleeding at 30 days (6.5% with LMWH versus
7.0% with heparin), but total bleeding was more frequent with the LMWH
group (18.4% versus 14.2%), primarily because of bruising at
injection sites. At 1 year, the difference in the composite end point
remained significant
(P=0.022).269
TIMI-11B (Thrombolysis In Myocardial Infarction 11B)270 was a double-blind study comparing enoxaparin (bolus followed by SC injections every 12 hours for 3 to 8 days) and IV heparin (administered for at least 3 days) in 3910 patients with unstable angina or non–Q-wave MI. The primary outcome was death, MI, or urgent revascularization at 43 days. Patients assigned to LMWH continued SC treatment at a lower dose until day 43, whereas patients assigned initially to heparin received placebo. There was an 18% relative risk reduction in events at 14 days (P=0.029) and a 12% risk reduction at 43 days (P=0.048). The absolute risk reductions were 2.4% and 2.3% at 14 and 43 days, respectively. The difference in treatment duration between UFH (3 days) and enoxaparin (43 days) and the validity of comparing event rates at 14 days render these data questionable. In addition, the lack of effectiveness of enoxaparin beyond 14 days is surprising and fails to establish a role for long-term use of LMWH in this patient population.271
Nadroparin was also evaluated in the FRAXIS (FRAXiparine in Ischaemic Syndrome) trial.272 Patients with unstable angina or non–Q-wave infarction were randomly assigned to receive full-dose SC nadroparin (every 12 hours on days 1 through 6, then placebo from day 7 to day 14), sustained SC nadroparin (every 12 hours for 14 days), or initial IV heparin (on days 1 through 6, followed by placebo until day 14). The incidence of the primary outcome (cardiovascular death, MI, and refractory or recurrent angina) was no different among the 3 groups at 6 days, and there was no difference between short- and long-term treatment with LMWH by 14 days.
Another recent trial evaluated long-term administration of LMWH compared with placebo. FRISC-II (Fragmin and Fast Revascularisation during InStability in Coronary artery disease) was a randomized, placebo-controlled trial of dalteparin in 2267 patients with unstable angina and non–Q-wave-MI.273 All patients received dalteparin 120 IU/kg every 12 hours for the acute phase (5 to 7 days) and then were randomized to dalteparin 5000 to 7500 IU every 12 hours or placebo for 90 days. The primary outcome was the composite of death and MI at 3 months. The primary outcome rates did not differ significantly between the dalteparin and placebo groups (6.7% versus 8.0%, P=0.17), but the rates of major and minor bleeding were significantly higher in patients who received dalteparin (3.3% versus 1.5%, P<0.01 and 23.0% versus 8.4%, P<0.001), respectively. A meta-analysis of the 2 trials of enoxaparin (ESSENCE268 and TIMI-11B270 ) showed that compared with UFH, enoxaparin produced a 20% relative reduction in rates of death and MI during the first 7 to 14 days of treatment.
The reason for the observed differences across trials that evaluated short-term LMWH compared with UFH in the presence of aspirin (the FRIC and FRAXIS versus ESSENCE and TIMI-11B studies) is not clear. Potential explanations include true therapeutic differences between the LMWH agents and differences in trial design, administration of UFH, and patient population, or the play of chance. To determine definitively whether enoxaparin is superior to other LMWH preparations would require head-to-head comparisons within 1 or more trials.
When all trials that compared short-term LMWH with UFH were
pooled (n=12 171), an OR of 0.85 (95% CI 0.70 to 1.04) was derived,
which suggests a modest 15% reduction with LMWH over UFH
(Figure 8). Data from 10 000 patients in long-term trials
do not indicate a benefit of LMWH over placebo in reducing MI or death
(OR 1.04; 95% CI 0.79 to 1.37;
Figure 9). It is of interest to consider these results with
LMWH in unstable angina and non–Q-wave MI in light of experience with
platelet GP IIb/IIIa antagonists and direct thrombin
inhibitors. Because LMWH has not been compared directly
with either of these classes of antithrombotic agents, however, only
indirect inferences are possible, and these may be
misleading.
Heparin has been compared with the synthetic GP IIb/IIIa blocker, iamifiban, in the PARAGON trial (Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network) 274 and with tirofiban in the PRISM trial (Platelet Receptor Inhibition in Ischemic Syndrome Management).275 When used alone, neither GP IIb/IIIa antagonist was more effective than heparin. The PURSUIT trial (Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy)276 evaluated 9450 patients and showed that a 72-hour infusion of Integrilin was associated with a 15% to 20% relative reduction in death and MI. Both the CAPTURE trial (C7E3 fab AntiPlatelet Therapy in Unstable REfractory angina),132 which evaluated abciximab in 1265 patients, and the PRISM-PLUS trial,131 which evaluated tirofiban in 1915 patients, focused on high-risk patients with unstable coronary artery disease. In both studies, GP IIb/IIIa inhibitors produced a 30% to 50% relative reduction in death or MI with treatment before and during revascularization.
Hirudin, a bivalent direct thrombin inhibitor, was evaluated in the OASIS-2 (Organization to Assess Strategies for Ischemic Syndromes) trial,104 a randomized study of 10 141 patients with unstable coronary artery disease assigned to either 72 hours of IV hirudin or standard heparin. There was a 10% to 20% relative reduction in the incidence of death or MI with hirudin in the first 3 to 7 days, but this was associated with an increase in bleeding (major bleeding in 1.2% versus 0.7% of patients and minor bleeding in 7.6% versus 4.5% of patients with hirudin and heparin, respectively).
Thus, 3 new classes of antithrombotic agents—LMWH (such as enoxaparin), platelet GP IIb/IIIa antagonists (such as abciximab), and thrombin inhibitors (such as hirudin)—are available for treatment of patients with unstable angina and non–Q-wave infarction. It appears that it is necessary to combine GP IIb/IIIa antagonists with heparin to achieve optimal efficacy. Because the efficacy of these new antithrombotic agents is limited to the initial period of acute treatment, the challenge is to develop safe and effective regimens that require simple or no monitoring and that are convenient for outpatient use to reduce the 15% risk of new MI over 3 months.
Q-Wave MI
Experience with LMWH in patients with acute Q-wave MI
is limited to 2 small studies in which the majority of patients
received thrombolytic therapy. The
Fragmin in Acute Myocardial Infarction (FRAMI)
study277 enrolled 776
patients with acute anterior MI in a randomized, double-blind
comparison of LMWH (dalteparin at 150 U/kg SC twice daily during
hospitalization) with placebo. Thrombolytic therapy
(streptokinase) and aspirin were administered to 91.5% and 97.6% of
patients, respectively. The mean time to the start of treatment was
12 hours in both the dalteparin and placebo groups. The primary end
point was the composite of left ventricular mural thrombus
formation diagnosed by echocardiography and
systemic arterial embolism by day 92. Of the 517 patients
with echocardiograms available for analysis, thrombus
formation, embolism, or both developed in 59 (21.9%) of 270 patients
in the placebo group and 35 (14.2%) of 247 patients receiving
dalteparin (P=0.03). Benefit
was predominantly a consequence of decreased left
ventricular thrombus formation. The relative risk of
thrombus formation with LMWH treatment was 0.63 (95% CI 0.43 to 0.92,
P=0.02). Analyses of
all randomized patients revealed no significant difference between
treatments with respect to arterial embolism (6 versus 5
patients, respectively), reinfarction (8 versus 6 patients), or death
(23 patients in each group). LMWH therapy was associated with an
increased risk of both major (2.9% versus 0.3%,
P=0.006) and minor (14.8%
versus 1.8%, P<0.001)
hemorrhage. One nonfatal and 2 fatal cerebral
hemorrhages (verified by CT scan) occurred in the LMWH group.
Thus, although LMWH reduced left ventricular thrombus
formation in patients with acute anterior MI, its use was associated
with a significantly increased risk of major hemorrhage,
possibly a consequence of concomitant thrombolytic
therapy and a higher dose of dalteparin than used in either the FRISC
or FRIC studies.
In a small study278 of 103 streptokinase-treated patients randomly assigned to enoxaparin (40 mg/d for 25 days) or placebo within 5 days of acute MI, 2 (4.3%) of 43 patients in the enoxaparin group developed recurrent MI within 30 days compared with 12 (20%) of 60 patients receiving placebo (P=0.02). The BIOMACS II study279 (Biochemical Markers in Acute Coronary Syndromes), a phase III clinical trial, is currently in progress in Scandinavia to address this issue.
Coronary Angioplasty
Studies in laboratory animals indicating that LMWH
suppresses neointimal proliferation after
arterial balloon
injury280 281
prompted clinical trials to evaluate the effect of LMWH on the rate of
restenosis after angioplasty. In the Enoxaparin
Restenosis after Angioplasty (ERA)
trial,282 patients were
randomly assigned to receive either 40 mg of enoxaparin or placebo SC
once daily for 1 month after successful coronary angioplasty.
Angiographic or clinical restenosis occurred in 51% of the 231
patients receiving placebo and 52% of the 227 patients receiving
enoxaparin (P=0.625). Although
major bleeding was more common in the enoxaparin group, the rate of
major bleeding did not differ significantly. The Enoxaparin and MaxEPA
for the Prevention of Angioplasty Restenosis (EMPAR)
study283 randomly allocated
653 patients to either enoxaparin (30 mg SC twice daily) or placebo for
6 weeks after successful angioplasty, with randomization to either fish
oil or control a median of 6 days earlier. Quantitative
coronary angiography revealed no significant difference in the
rate of restenosis either per patient or per lesion. The
results of these 2 negative studies leave little doubt as to the lack
of efficacy of enoxaparin in preventing restenosis when used in
doses of up to 60 mg/d (6000 anti-factor Xa U/d) for 6
weeks.
Atrial Fibrillation
The multicenter, randomized, double-blind Heparin in
Acute Embolic Stroke Trial
(HAEST)284 found no
evidence that LMWH is superior to aspirin for treatment of acute
ischemic stroke in patients with AF. In that study, either the
LMWH, dalteparin (100 U/kg SC twice daily), or aspirin (160 mg/d) was
started within 30 hours of stroke onset in 449 patients with AF and
acute ischemic stroke. The frequency of recurrent
ischemic stroke during the first 14 days was 8.5% in
dalteparin-allocated patients versus 7.5% in aspirin-allocated
patients (OR 1.13, 95% CI 0.57 to 2.24). There was no benefit of
dalteparin compared with aspirin in reducing cerebral
hemorrhage (12% versus 14%), progression of symptoms within
the first 48 hours (11% versus 8%), or death (9% versus 7%, all
P=NS) or functional outcome at
14 days or 3 months.
LMWH has also been used in patients with AF as an adjunct to the strategy of transesophageal echocardiography–guided cardioversion but has not been specifically evaluated in a controlled trial. In one observational series,285 242 patients referred for cardioversion of AF or flutter without prior anticoagulation were examined by transesophageal echocardiography. Those subjected to prompt cardioversion (n=162; mean age 62 years) were younger than others treated conventionally with warfarin before cardioversion (n=80; mean age 67 years; P<0.05) and more often had "lone" AF or flutter without associated heart disease (53% versus 34%, P<0.05). Dalteparin was administered together with warfarin before early cardioversion of these low-risk patients and continued until the international normalized ratio reached the therapeutic range. Although no ischemic events were observed, more systematic experience must be gained in AF patients across a broader range of intrinsic thromboembolic risk before LMWH can be routinely advocated before cardioversion.
|
Conclusions |
|---|
LMWH preparations are at least as effective and safe as UFH and more convenient, although they have the disadvantage of expense. The higher cost of the drug itself cannot be considered in isolation, however, because savings from SC administration and reduced hospital stay offset this. One appealing feature of LMWH is a more predictable dose response relative to UFH, which translates clinically into weight-adjusted dosing without laboratory monitoring. The only study that compared the predictability of the dose response of LMWH with that of UFH173 demonstrated less variability, but this was not abolished entirely. The efficacy and safety of LMWH might be improved by monitoring anti-factor Xa levels, but the anticipated improvement in clinical outcome would likely be marginal and balanced by inconvenience and added expense. Weight-adjusted dosing could be misleading in patients with renal insufficiency and in obese patients. Further studies are required to determine whether monitoring is necessary in such patients. Based on current information, however, LMWH preparations should be administered with weight-adjusted dosing in the majority of patients.
|
Footnotes |
|---|
This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in December 2000. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0203. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1466, fax 214-691-6342, or . To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.
Parts of this statement were originally published in Circulation. 1994;89:1449–1468. This publication is an update of the 1994 statement.
Parts of this statement are based on the Sixth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy and have been published previously in Chest (2001;119[suppl]:64S–94S).
This statement will also be published in the July 2001 issue of Arteriosclerosis, Thrombosis, and Vascular Biology.
|
References |
|---|
1. Badimon L, Badimon JJ, Fuster V. Pathogenesis of thrombosis. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders Co; 1992:17–39.
2. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders Co; 1992:1–16.
3. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res. 1973;5:167–179.[Medline] [Order article via Infotrieve]
4. Badimon L, Badimon JJ. Mechanism of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall: experimental study in the pig model. J Clin Invest. 1989;84:1134–1144.
5.
Lassila R, Badimon
JJ, Vallabhajosula S, et al. Dynamic monitoring of platelet
deposition on severely damaged vessel wall in flowing blood: effects of
different stenoses on thrombus growth.
Arteriosclerosis. 1990;10:306–315.
6. Jorgensen L, Rowsell HC, Hovig T, et al. Resolution and organization of platelet-rich mural thrombi in carotid arteries of swine. Am J Pathol. 1967;51:681–719.[Medline] [Order article via Infotrieve]
7. Constantinides P. Plaque fissures in human coronary thrombosis. J Atheroscler Res. 1966;6:1–17.
8. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes, part I. N Engl J Med. 1992;326:242–250.[Medline] [Order article via Infotrieve]
9. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;2:941–944.[Medline] [Order article via Infotrieve]
10. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol. 1989;663:114E–120E.
11.
Falk E. Unstable
angina with fatal outcome: dynamic coronary thrombosis leading
to infarction and/or sudden death: autopsy evidence of recurrent mural
thrombosis with peripheral embolization culminating in
total vascular occlusion.
Circulation. 1985;71:699–708.
12.
Davies MJ,
Thomas AC, Knapman PA, et al. Intramyocardial platelet
aggregation in patients with unstable angina suffering sudden
ischemic cardiac death.
Circulation. 1986;73:418–427.
13. Roberts WC, Buja LM. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction: a study of 107 necropsy patients. Am J Med. 1972;52:425–443.[Medline] [Order article via Infotrieve]
14.
Anderson FA,
Wheeler HB, Goldberg RJ, et al. A population-based perspective of the
incidence and case-fatality rates of deep vein thrombosis and
pulmonary embolism: the Worcester DVT Study.
Arch Intern Med. 1991;151:933–938.
15. McLean J. The thromboplastic action of cephalin. Am J Physiol. 1916;41:250–257.
16. Brinkhous KM, Smith HP, Warner ED, et al. The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. Am J Physiol. 1939;125:683–687.
17. Abildgaard U. Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest. 1968;21:89–91.[Medline] [Order article via Infotrieve]
18. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, Pa: JB Lippincott Co; 1994:837–860.
19.
Rosenberg RD, Lam
L. Correlation between structure and function of heparin.
Proc Natl Acad Sci
U S A. 1979;76:1218–1222.
20.
Lindahl U,
Backstrom G, Hook M, et al. Structure of the antithrombin-binding site
of heparin. Proc Natl Acad Sci
U S A. 1979;76:3198–3202.
21. Casu B, Oreste P, Torri G, et al. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence: chemical and 13C nuclear-magnetic-resonance studies. Biochem J. 1981;97:599–609.
22. Choay J, Lormeau JC, Petitou M, et al. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann N Y Acad Sci. 1981;370:644–649.[Medline] [Order article via Infotrieve]
23. Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: a pilot study in the setting of coronary angioplasty. Thromb Haemost. 1999;81:214–220.[Medline] [Order article via Infotrieve]
24.
Herbert JM,
Herault JP, Bernat A, et al. Biochemical and pharmacological properties
of SANORG 34006, a potent and long-acting synthetic
pentasaccharide. Blood. 1998;91:4197–4205.
25. Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun. 1976;69:570–577.[Medline] [Order article via Infotrieve]
26. Andersson LO, Barrowcliffe TW, Holmer E, et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res. 1976;9:575–583.[Medline] [Order article via Infotrieve]
27.
Tollefsen DM,
Majerus DW, Blank MK. Heparin cofactor II: purification and properties
of a heparin-dependent inhibitor of thrombin in human
plasma. J Biol Chem. 1982;257:2162–2169.
28.
Lindahl U,
Thunberg L, Backstrom G, et al. Extension and structural variability of
the antithrombin-binding sequence in heparin.
J Biol Chem. 1984;259:12368–12376.
29. Lane DA, Denton J, Flynn AM, et al. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J. 1984;218:725–732.[Medline] [Order article via Infotrieve]
30.
Oosta GM, Gardner
WT, Beeler DL, et al. Multiple functional domains of the heparin
molecule. Proc Natl Acad Sci
U S A. 1981;78:829–833.
31.
Nesheim ME. A
simple rate law that describes the kinetics of the heparin-catalyzed
reaction between antithrombin III and thrombin.
J Biol Chem. 1983;258:14708–14717.
32. Ofosu FA, Sie P, Modi GJ, et al. The inhibition of thrombin-dependent positive feedback reactions is critical to the expression of anticoagulant effects of heparin. Biochem J. 1987;243:579–588.[Medline] [Order article via Infotrieve]
33. Ofosu FA, Hirsh J, Esmon CT, et al. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J. 1989;257:143–150.[Medline] [Order article via Infotrieve]
34. Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost. 1988;60:457–462.[Medline] [Order article via Infotrieve]
35. Andersson LO, Barrowcliffe TW, Holmer E, et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X: effect of heparin neutralization in plasma. Thromb Res. 1979;5:531–541.
36. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost. 1990;16:12–18.
37. Johnson EA, Mulloy B. The molecular weight range of mucosal heparin preparations. Carbohydr Res. 1976;51:119–127.[Medline] [Order article via Infotrieve]
38. Eika C. Inhibition of thrombin-induced aggregation of human platelets by heparin. Scand J Haematol. 1971;8:216–222.[Medline] [Order article via Infotrieve]
39. Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol. 1980;17:259–291.[Medline] [Order article via Infotrieve]
40. Salzman EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980;65:64–73.
41. Heiden D, Mielke CH, Rodvien R. Impairment by heparin of primary haemostasis and platelet (14C)5-hydroxytryptamine release. Br J Haematol. 1977;36:427–436.[Medline] [Order article via Infotrieve]
42. Fernandez F, Nguyen P, Van Ryn J, et al. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res. 1986;43:491–495.[Medline] [Order article via Infotrieve]
43. Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci. 1989;556:245–254.[Medline] [Order article via Infotrieve]
44. Ockelford PA, Carter CJ, Cerskus A, et al. Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin III affinity heparin fraction. Thromb Res. 1982;27:679–690.[Medline] [Order article via Infotrieve]
45. Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977;265:625–626.[Medline] [Order article via Infotrieve]
46.
Shaughnessy SG,
Young E, Deschamps P, et al. The effects of low molecular weight and
standard heparin on calcium loss from the fetal rat calvaria.
Blood. 1995;86:1368–1373.
47. Bhandari M, Hirsh J, Weitz JI, et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost. 1998;80:413–417.[Medline] [Order article via Infotrieve]
48.
Castellot
JJ, Favreau LV, Karnovsky MJ, et al. Inhibition of vascular smooth
muscle cell growth by endothelial cell-derived heparin:
possible role of a platelet endoglycosidase.
J Biol Chem. 1982;257:11256–11260.
49. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109–1114.[Abstract]
50.
Hirsh J, van Aken
WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and
pulmonary embolism.
Circulation. 1976;53:691–695.
51. Young E, Prins M, Levine MN, et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992;67:639–643.[Medline] [Order article via Infotrieve]
52. Barzu T, Molho P, Tobelem G, et al. Binding and endocytosis of heparin by human endothelial cells in culture. Biochem Biophys Acta. 1985;845:196–203.[Medline] [Order article via Infotrieve]
53. Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest. 1991;87:1787–1793.
54.
de Swart CA,
Nijmeyer B, Roelofs JM, et al. Kinetics of intravenously
administered heparin in normal humans.
Blood. 1982;60:1251–1258.
55. Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin: an experimental study on dogs and humans. Acta Med Scand. 1963;173:619–630.[Medline] [Order article via Infotrieve]
56. Bjornsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther. 1982;31:104–113.[Medline] [Order article via Infotrieve]
57. Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res. 1978;12:773–782.[Medline] [Order article via Infotrieve]
58. Mahadoo J, Heibert L, Jaques LB. Vascular sequestration of heparin. Thromb Res. 1978;12:79–90.[Medline] [Order article via Infotrieve]
59. Friedman Y, Arsenis C. Studies on the heparin sulphamidase activity from rat spleen: intracellular distribution and characterization of the enzyme. Biochem J. 1974;139:699–708.[Medline] [Order article via Infotrieve]
60. Dawes J, Popper DS. Catabolism of low-dose heparin in man. Thromb Res. 1979;14:845–860.[Medline] [Order article via Infotrieve]
61. McAllister BM, Demis DJ. Heparin metabolism: isolation and characterization of uroheparin. Nature. 1966;212:293–294.[Medline] [Order article via Infotrieve]
62. Bara L, Billaud E, Gramond G, et al. Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res. 1985;39:631–636.[Medline] [Order article via Infotrieve]
63. Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989;320:352–357.[Abstract]
64. Pini M, Pattachini C, Quintavalla R, et al. Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis: a randomized clinical trial. Thromb Haemost. 1990;64:222–226.[Medline] [Order article via Infotrieve]
65. Levine MN, Hirsh J, Kelton JG. Heparin-induced bleeding. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties, Clinical Applications. London, UK: Edward Arnold; 1989:517–532.
66. Morabia A. Heparin doses and major bleedings. Lancet. 1986;1:1278–1279.[Medline] [Order article via Infotrieve]
67.
GUSTO IIA
Investigators. Randomized trial of intravenous heparin
versus recombinant hirudin for acute coronary syndromes.
Circulation. 1994;90:1631–1637.
68.
Antman EM, and
the TIMI 9A Investigators. Hirudin in acute myocardial infarction:
safety report from the Thrombolysis and Thrombin Inhibition
in Myocardial Infarction (TIMI) 9A trial.
Circulation. 1994;90:1624–1630.
69.
GUSTO IIB
Investigators, Topol E, Califf R, et al. A comparison of recombinant
hirudin with heparin for the treatment of acute coronary
syndromes. N Engl J
Med. 1996;335:775–782.
70.
Antman EM, and
the TIMI 9B Investigators. Hirudin in acute myocardial infarction:
Thrombolysis and Thrombin Inhibition in Myocardial
Infarction (TIMI) 9B trial.
Circulation. 1996;94:911–921.
71.
EPIC
Investigators. Use of a monoclonal antibody directed against the
platelet glycoprotein IIb/IIIa receptor in high-risk
coronary angioplasty. N Engl
J Med. 1994;330:956–961.
72.
EPILOG
Investigators. Platelet glycoprotein IIb/IIIa receptor
blockade and low-dose heparin during percutaneous
coronary revascularization.
N Engl J Med. 1997;336:1689–1696.
73. Landefeld CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 1987;82:703–723.[Medline] [Order article via Infotrieve]
74.
Raschke RA,
Gollihare B, Peirce JC. The effectiveness of implementing the
weight-based heparin nomogram as a practice guideline.
Arch Intern Med. 1996;156:1645–1649.
75. Camilleri JF, Bonnet JL, Bouvier JL, et al. Thrombolyse intraveineuse dans l’infarctus du myocarde: influence de la qualite de l’antiocoagulation sur le taux de recidives precoces d’angor ou d’infarctus. Arch Mal Coeur. 1988;81:1037–1041.
76. Kaplan K, Davison R, Parker M, et al. Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction. Am J Cardiol. 1987;59:241–244.[Medline] [Order article via Infotrieve]
77.
de Bono DP,
Simoons ML, Tijssen J, et al, and the European Cooperative Study Group.
Effect of early intravenous heparin on coronary
patency, infarct size, and bleeding complications after alteplase
thrombolysis: results of a randomised double blind
European Cooperative Study Group trial. Br
Heart J. 1992;67:122–128.
78. Arnout J, Simoons M, de Bono D, et al. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol. 1992;20:513–519.[Abstract]
79. Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287:324–327.
80.
Levine MN, Hirsh
J, Gent M, et al. A randomized trial comparing activated
thromboplastin time with heparin assay in patients with acute venous
thromboembolism requiring large daily doses of heparin.
Arch Intern Med. 1994;154:49–56.
81.
Anand S, Ginsberg
JS, Kearon C, et al. The relation between the activated partial
thromboplastin time response and recurrence in patients with
venous thrombosis treated with continuous intravenous
heparin. Arch Intern Med. 1996;156:1677–1681.
82.
Anand SS, Bates
S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy:
an evaluation of the importance of early activated partial
thromboplastin times. Arch Intern
Med. 1999;159:2029–2032.
83.
GUSTO
Investigators. An international randomized trial comparing four
thrombolytic strategies for acute myocardial
infarction. N Engl J
Med. 1993;329:673–682.
84.
Brill-Edwards P,
Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for
heparin therapy. Ann Intern
Med. 1993;119:104–109.
85.
Hirsh J.
Low-molecular-weight heparin: a review of the results of recent studies
of the treatment of venous thromboembolism and unstable angina.
Circulation. 1998;98:1575–1582.
86.
Cruickshank MK,
Levine MN, Hirsh J, et al. A standard heparin nomogram for the
management of heparin therapy. Arch Intern
Med. 1991;151:333–337.
87.
Ryan TJ, Antman
EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the
management of patients with acute myocardial infarction: a report of
the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on Management
of Acute Myocardial Infarction). J Am
Coll Cardiol. 1999;34:890–911.
88.
Hirsh J,
Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight
heparin: mechanisms of action, pharmacokinetics, dosing considerations,
monitoring, efficacy, and safety.
Chest. 1998;114:489S–510S.
89. Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 1994;71:300–304.[Medline] [Order article via Infotrieve]
90. Lane DA. Heparin binding and neutralizing protein. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties, Clinical Applications. London, UK: Edward Arnold; 1989:363–374.
91. Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81–88.
92. Greinacher A, Potzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247–251.[Medline] [Order article via Infotrieve]
93.
Hirsh J, Levine
MN. Low molecular weight heparin.
Blood. 1992;79:1–17.
94. Hirsh J, Weitz JI. New antithrombotic agents. Lancet. 1999;353:1431–1436.[Medline] [Order article via Infotrieve]
95. Marciniak E. Factor Xa inactivation by antithrombin 3: evidence for biological stabilization of factor Xa by factor V-phospholipid complex. Br J Haematol. 1973;24:391–400.[Medline] [Order article via Infotrieve]
96. Walker FJ, Esmon CT. The effects of phospholipid and factor Va on the inhibition of factor Xa by antithrombin III. Biochem Biophys Res Commun. 1979;90:641–647.[Medline] [Order article via Infotrieve]
97.
Lane DA, Pejler
G, Flynn AM, et al. Neutralization of heparin-related
saccharides by histidine-rich glycoprotein and
platelet factor 4. J Biol
Chem. 1986;261:3980–3986.
98. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385–391.
99.
Hogg PJ,
Jackson CM. Fibrin monomer protects thrombin from inactivation by
heparin-antithrombin III: implications for heparin efficacy.
Proc Natl Acad Sci
U S A. 1989;86:3619–3623.
100.
Becker DL,
Fredenburgh JC, Stafford AR, et al. Exosites 1 and 2 are essential for
protection of fibrin-bound thrombin from heparin-catalyzed inhibition
by antithrombin and heparin cofactor II.
J Biol Chem. 1999;274:6226–6233.
101. Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties. J Clin Invest. 1989;84:1096–1104.
102.
Heras M,
Chesebro JH, Penny WJ, et al. Effects of thrombin inhibition on the
development of acute platelet-thrombus deposition during
angioplasty in pigs: heparin versus recombinant hirudin, a specific
thrombin inhibitor.
Circulation. 1989;79:657–665.
103. Agnelli G, Pascucci C, Cosmi B, et al. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost. 1990;63:204–207.[Medline] [Order article via Infotrieve]
104. OASIS-2 Investigators. Effect of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet. 1999;353:429–438.[Medline] [Order article via Infotrieve]
105.
Chiu HM, Hirsh
J, Yung WL, et al. Relationship between the anticoagulant and
antithrombotic effects of heparin in experimental venous thrombosis.
Blood. 1977;49:171–184.
106. Barritt DW, Jordon SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet. 1960;1:1309–1312.[Medline] [Order article via Infotrieve]
107. Brandjes DP, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med. 1992;327:1485–1489.[Abstract]
108. Salzman EW, Deykin D, Shapiro RM, et al. Management of heparin therapy: controlled prospective trial. N Engl J Med. 1975;292:1046–1050.[Abstract]
109.
Glazier RL,
Corwell EB. Randomized prospective trial of continuous vs intermittent
heparin therapy. JAMA. 1976;236:1365–1367.
110. Mant MJ, O’Brien BD, Thong KL, et al. Haemorrhagic complications of heparin therapy. Lancet. 1977;1:1133–1135.[Medline] [Order article via Infotrieve]
111. Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. Am Heart J. 1979;97:155–158.[Medline] [Order article via Infotrieve]
112. Fagher B, Lundh B. Heparin treatment of deep vein thrombosis: effects and complications after continuous or intermittent heparin administration. Acta Med Scand. 1981;210:357–361.[Medline] [Order article via Infotrieve]
113. Wilson JE, Bynum LJ, Parkey RW. Heparin therapy in venous thromboembolism. Am J Med. 1981;70:808–816.[Medline] [Order article via Infotrieve]
114. Krahenbuhl B, Simon CA, Bouvier CA, et al. Traitement heparinique: comparaison entre les voies d’admistration intraveineuse et souscutanee. Schweiz Med Wochenschr. 1979;109:1322–1325.[Medline] [Order article via Infotrieve]
115. Doyle DJ, Turpie AG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: a randomized trial. Ann Intern Med. 1987;107:441–445.
116. Bentley PG, Kakkar VV, Scully MF, et al. An objective study of alternative methods of heparin administration. Thromb Res. 1980;18:177–187.[Medline] [Order article via Infotrieve]
117. Andersson G, Fagrell B, Holmgren K, et al. Subcutaneous administration of heparin: a randomised comparison with intravenous administration of heparin to patients with deep vein thrombosis. Thromb Res. 1982;27:631–639.[Medline] [Order article via Infotrieve]
118. Walker MG, Shaw JW, Thomson GJ, et al. Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomized trial. Br Med J. 1987;294:1189–1192.
119.
Gould MK,
Dembitzer AD, Doyle RL, et al. Low molecular weight heparins compared
with unfractionated heparin for the treatment of acute deep venous
thrombosis: a meta-analysis of randomized controlled trials.
Ann Intern Med. 1999;130:800–809.
120. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260–1264.[Abstract]
121. Gallus A, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986;2:1293–1296.[Medline] [Order article via Infotrieve]
122. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg. 1988;208:227–240.[Medline] [Order article via Infotrieve]
123. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988;318:1162–1173.[Medline] [Order article via Infotrieve]
124. Kakkar VV, Corrigan TP, Fossard DP. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an international multicentre trial. Lancet. 1975;2:45–51.[Medline] [Order article via Infotrieve]
125. Gallus AS. Overview of the management of thrombotic disorders. Semin Thromb Hemost. 1989;15:99–110.
126. Halkin H, Goldberg J, Modan M, et al. Reduction of mortality in general medical inpatients by low-dose heparin prophylaxis. Ann Intern Med. 1982;96:561–565.
127. Leyvraz PF, Richard J, Bachmann F. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement. N Engl J Med. 1983;309:954–958.[Abstract]
128.
Powers PJ, Gent
M, Jay RM, et al. A randomized trial of less intense postoperative
warfarin or aspirin therapy in the prevention of venous thromboembolism
after surgery for fractured hip. Arch
Intern Med. 1989;149:771–774.
129.
Francis CW,
Marder VJ, Evarts CM, et al. Two-step warfarin therapy: prevention of
postoperative venous thrombosis without excessive bleeding.
JAMA. 1983;249:374–378.
130.
Oler A, Whooley
MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of
myocardial infarction and death in patients with unstable angina: a
meta-analysis. JAMA. 1996;276:811–815.
131.
PRISM PLUS
Study Investigators. Inhibition of the platelet
glycoprotein IIb/IIIa receptor with tirofiban in unstable
angina and non–Q-wave myocardial infarction.
N Engl J Med. 1998;338:1488–1497.
132. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429–1435.[Medline] [Order article via Infotrieve]
133.
Collins R, Peto
R, Baigent C, et al. Aspirin, heparin, and fibrinolytic therapy in
suspected acute myocardial infarction.
N Engl J Med. 1997;336:847–860.
134. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827–830.[Medline] [Order article via Infotrieve]
135. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–1111.[Abstract]
136. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:141–145.[Abstract]
137. Neri Serneri GG, Gensini GF, Poggesi L, et al. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet. 1990;335:615–618.[Medline] [Order article via Infotrieve]
138. Theroux P, Waters D, Qiu S, et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993;99:2045–2048.
139.
Cohen M, Adams
PC, Parry G, et al. Combination antithrombotic therapy in unstable rest
angina and non–Q-wave infarction in nonprior aspirin users: primary
end points analysis from the ATACS trial: Antithrombotic
Therapy in Acute Coronary Syndromes Research Group.
Circulation. 1994;89:81–88.
140. MacMahon S, Collins R, Knight C, et al. Reduction in major morbidity and mortality by heparin in acute myocardial infarction. Circulation. 1988;78(suppl II):II-98. Abstract.
141. Neri Serneri GG, Roveli F, Gensini GF, et al. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet. 1987;1:937–942.[Medline] [Order article via Infotrieve]
142. The SCATI (Studio sulla Calciparina nell’Angina e nella Thrombosi Ventricolare nell’Infarto) Group. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet. 1989;2:182–186.[Medline] [Order article via Infotrieve]
143.
Topol EJ,
George BS, Kereiakes DJ, et al, and the TAMI Study Group. A randomized
controlled trial of intravenous tissue
plasminogen activator and early
intravenous heparin in acute myocardial infarction.
Circulation. 1989;79:281–286.
144. Bleich SD, Nichols TC, Schumacher RR, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990;66:1412–1417.[Medline] [Order article via Infotrieve]
145. Hsia J, Hamilton WP, Kleiman N, et al, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1990;323:1433–1437.[Abstract]
146. The Australian National Heart Study Trial. A randomized comparison of oral aspirin/dipyridamole versus intravenous heparin after rtPA for acute myocardial infarction. Circulation. 1989;80(suppl II):II-114. Abstract.
147. Col J, Decoster O, Hanique G, et al. Infusion of heparin conjunct to streptokinase accelerates reperfusion of acute myocardial infarction: results of a double blind randomized study (OSIRIS). Circulation. 1992;(suppl):I-259. Abstract.
148. O’Connor CM, Meese R, Carney R, et al. A randomized trial of intravenous heparin in conjunction with anistreplase (anisolyated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS). J Am Coll Cardiol. 1994;29:11–18.
149. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet. 1990;336:71–75.[Medline] [Order article via Infotrieve]
150. ISIS-3 Collaborative Group. ISIS-3: randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753–770.[Medline] [Order article via Infotrieve]
151. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682.
152. O’Connor C, for the DUCCS Study Group. Duke University Clinical Cardiology Studies (DUCCS-1). Presented at: American Heart Association; 1992; Anaheim, Calif.
153.
Collins R,
MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy
in suspected acute myocardial infarction: systematic overview of
randomised trials. BMJ. 1996;313:652–659.
154. Kruse KR, Califf RM, Ohman EM. Adjunctive therapies. In: Thrombolytic Therapy: A Critical Review of Clinical Trials. 19XX:459–471.
155. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol. 1996;77:551–556.[Medline] [Order article via Infotrieve]
156. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328–1428.[Medline] [Order article via Infotrieve]
157.
Nairns CR,
Hillegass WBJ, Nelson CL, et al. Relation between activated
clotting time during angioplasty and abrupt closure.
Circulation. 1996;93:667–671.
158.
Doucet S,
Malekianpour M, Theroux P, et al. Randomized trial comparing
intravenous nitroglycerin and heparin for
treatment of unstable angina secondary to restenosis after
coronary artery angioplasty.
Circulation. 2000;101:955–961.
159. Mitusch R, Siemens HJ, Garbe M, et al. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost. 1996;75:219–223.[Medline] [Order article via Infotrieve]
160. Douketis JD, Crowther MA, Cherian SS. Perioperative anticoagulation in patients with chronic atrial fibrillation who are undergoing elective surgery: results of a physician survey. Can J Cardiol. 2000;16:326–330.[Medline] [Order article via Infotrieve]
161. Koudstaal PJ, Koudstaal A. Secondary stroke prevention in atrial fibrillation: indications, risks, and benefits. J Thromb Thrombolysis. 1999;7:61–65.[Medline] [Order article via Infotrieve]
162.
Babikian
VL, Kase CS, Pessin MS, et al. Intracerebral
hemorrhage in stroke patients anticoagulated with heparin.
Stroke. 1989;20:1500–1503.
163.
Albers GW,
Bittar N, Young L, et al. Clinical characteristics and management of
acute stroke in patients with atrial fibrillation admitted to US
university hospitals.
Neurology. 1997;48:1598–1604.
164.
Chamorro A,
Vila N, Ascaso C, et al. Heparin in acute stroke with atrial
fibrillation: clinical relevance of very early treatment.
Arch Neurol. 1999;56:1098–1102.
165.
Jaillard A,
Cornu C, Durieux A, et al. Hemorrhagic transformation in acute
ischemic stroke: the MAST-E study.
Stroke. 1999;30:1326–1332.
166. Kerber RE. Transthoracic cardioversion of atrial fibrillation and flutter: standard techniques and new advances. Am J Cardiol. 1996;78:22–26.[Medline] [Order article via Infotrieve]
167.
Mayet J, More
RS, Sutton GC. Anticoagulation for cardioversion of atrial
arrhythmias. Eur Heart
J. 1998;19:548–552.
168. Manning WJ, Silverman DI, Keighley CS, et al. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol. 1995;25:1354–1361.[Abstract]
169. Zhou L, Keane D, Reed G, et al. Thromboembolic complications of cardiac radiofrequency catheter ablation: a review of the reported incidence, pathogenesis and current research directions. J Cardiovasc Electrophysiol. 1999;10:611–620.[Medline] [Order article via Infotrieve]
170. Keane D, Zhou L, Ruskin J. Catheter ablation of atrial fibrillation. Semin Interv Cardiol. 1997;2:251–265.[Medline] [Order article via Infotrieve]
171. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79:1–7.[Medline] [Order article via Infotrieve]
172. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999;82(suppl):439–447.
173. Warkentin TE, Levine MN, Hirsh J, et al. Formation of heparin-induced thrombocytopenia IgG without thrombocytopenia: analysis of a clinical trial. Blood. 1995;86(suppl 1):537a. Abstract.
174. Warkentin TE. Heparin-induced skin lesions. Br J Haematol. 1996;92:494–497.[Medline] [Order article via Infotrieve]
175.
Warkentin TE,
Sheppard JA, Horsewood P, et al. Impact of the patient population on
the risk of heparin-induced thrombocytopenia.
Blood. 2000;96:1703–1708.
176. Lee DP, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York, NY: Marcel Dekker; 2000:81–112.
177. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95–96.[Medline] [Order article via Infotrieve]
178. Amiral J, Meyer D. Heparin-dependent antigens in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York, NY: Marcel Dekker; 2000:127–138.
179. Visentin GP, Bacsi S, Aster RH. Molecular immunopathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York, NY: Marcel Dekker; 2000:139–154.
180.
Chong BH,
Murray B, Berndt MC, et al. Plasma P-selectin is increased in
thrombotic consumptive platelet disorders.
Blood. 1994;83:1535–1541.
181.
Warkentin TE,
Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced
thrombocytopenia generate platelet-derived microparticles with
procoagulant activity: an explanation for the thrombotic complications
of heparin-induced thrombocytopenia.
Blood. 1994;84:3691–3699.
182.
Kelton JG,
Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia:
laboratory studies. Blood. 1988;72:925–930.
183.
Warkentin TE,
Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients
treated with low-molecular-weight heparin or unfractionated heparin.
N Engl J Med. 1995;332:1330–1335.
184. Funk S, Eichler P, Albrecht D, et al. Heparin-induced thrombocytopenia (HIT) in orthopedic patients: a prospective cohort trial comparing UFH and LMWH. Ann Hematol. 2000;79(suppl 1):A92. Abstract.
185. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York, NY: Marcel Dekker; 2000:211–244.
186. Griffiths E, Dzik WH. Assays for heparin-induced thrombocytopenia. Transfus Med. 1997;7:1–11.
187. Warkentin TE, Hayward CP, Smith CA, et al. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med. 1992;120:371–379.[Medline] [Order article via Infotrieve]
188. Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion. 1994;34:381–385.[Medline] [Order article via Infotrieve]
189. Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost. 1999;81:625–629.[Medline] [Order article via Infotrieve]
190. Collins JL, Aster RH, Moghaddam M, et al. Diagnostic testing for heparin-induced thrombocytopenia (HIT): an enhanced platelet factor 4 complex enzyme linked immunosorbent assay (PF ELISA). Blood. 1997;90(suppl 1):461a. Abstract.
191. Greinacher A. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. New York, NY: Marcel Dekker; 2000:313–338.
192.
Greinacher A,
Völpel H, Janssens U, et al, for the HIT Investigators Group.
Recombinant hirudin (lepirudin) provides safe and effective
anticoagulation in patients with heparin-induced thrombocytopenia: a
prospective study. Circulation. 1999;99:73–80.
193.
Greinacher A,
Janssens U, Berg G, et al, for the Heparin-Associated Thrombocytopenia
Study (HAT) Investigators. Lepirudin (recombinant hirudin) for
parenteral anticoagulation in patients with heparin-induced
thrombocytopenia. Circulation. 1999;100:587–593.
194.
Greinacher A,
Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with
thromboembolic complications: meta-analysis of 2
prospective trials to assess the value of parenteral treatment with
lepirudin and its therapeutic aPTT range.
Blood. 2000;96:846–851.
195. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502–507.[Medline] [Order article via Infotrieve]
196. Boon DM, Michiels JJ, Stibbe J, et al. Heparin-induced thrombocytopenia and antithrombotic therapy. Lancet. 1994;344:1296. Letter.
197. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106:629–635.[Medline] [Order article via Infotrieve]
198. Johnson EA, Kirkwood TB, Stirling Y, et al. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost. 1976;35:586–591.[Medline] [Order article via Infotrieve]
199.
Carter CJ,
Kelton JG, Hirsh J, et al. The relationship between the hemorrhagic and
antithrombotic properties of low molecular weight heparins in rabbits.
Blood. 1982;59:1239–1245.
200. Esquivel CO, Bergqvist D, Bjorck CG, et al. Comparison between commercial heparin, low-molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo. Thromb Res. 1982;28:389–399.[Medline] [Order article via Infotrieve]
201. Cade JF, Buchanan MR, Boneu B, et al. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res. 1984;35:613–625.[Medline] [Order article via Infotrieve]
202. Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res. 1982;25:475–485.[Medline] [Order article via Infotrieve]
203. Andriuoli G, Mastacchi R, Barbanti M, et al. Comparison of the antithrombotic and hemorrhagic effects of heparin and a new low molecular weight heparin in the rat. Haemostasis. 1985;15:324–330.[Medline] [Order article via Infotrieve]
204. Bergqvist D, Nilsson B, Hedner U, et al. The effects of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res. 1985;38:589–601.[Medline] [Order article via Infotrieve]
205. Frydman AM, Bara L, LeRoux Y, et al. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin in humans given single subcutaneous doses of 20 up to 80 mg. J Clin Pharmacol. 1988;28:609–618.[Abstract]
206. Briant L, Caranobe C, Saivin S, et al. Unfractionated heparin and CY216: pharmacokinetics and bioavailabilities of the anti-factor Xa and IIa: effects after intravenous and subcutaneous injection in rabbits. Thromb Haemost. 1989;61:348–353.[Medline] [Order article via Infotrieve]
207. Bratt G, Tornebohm E, Widlund L, et al. Low molecular weight heparin (KABI 2165, FRAGMIN): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res. 1986;42:613–620.[Medline] [Order article via Infotrieve]
208. Matzsch T, Bergqvist D, Hedner U, et al. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost. 1987;57:97–101.[Medline] [Order article via Infotrieve]
209. Bara L, Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl. 1988;543:65–72.[Medline] [Order article via Infotrieve]
210. Bradbrook ID, Magnani HN, Moelker HC, et al. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half life in man. Br J Clin Pharmacol. 1987;23:667–675.[Medline] [Order article via Infotrieve]
211.
Weitz JI.
Low-molecular-weight heparins. N Engl
J Med. 1997;337:688–698.
212.
Jordan RE,
Oosta GM, Gardner WT, et al. The kinetics of hemostatic
enzyme-antithrombin interactions in the presence of low molecular
weight heparin. J Biol
Chem. 1980;255:10081–10090.
213. Holmer E, Kurachi K, Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J. 1981;193:395–400.[Medline] [Order article via Infotrieve]
214. Holmer E, Soderberg K, Bergqvist D, et al. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis. 1986;16(suppl 2):1–7.
215.
Griffith
MJ. Heparin-catalyzed inhibitor/protease reactions:
kinetic evidence for a common mechanism of action of heparin.
Proc Natl Acad Sci
U S A. 1983;80:5460–5464.
216.
Pletcher CH,
Nelsestuen GL. Two-substrate reaction model for the heparin-catalyzed
bovine antithrombin/protease reaction.
J Biol Chem. 1983;258:1086–1091.
217. Handeland GF, Abildgaard GF, Holm HA, et al. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol. 1990;39:107–112.[Medline] [Order article via Infotrieve]
218. Rosenberg RD, Jordon RE, Favreau LV, et al. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun. 1979;86:1319–1324.[Medline] [Order article via Infotrieve]
219.
Danielsson A,
Raub E, Lindahl U, et al. Role of ternary complexes in which heparin
binds both antithrombin and proteinase in the acceleration of the
reactions between antithrombin and thrombin or factor Xa.
J Biol Chem. 1986;261:15467–15473.
220.
Jordan RE,
Favreau LV, Braswell EH, et al. Heparin with two binding sites for
antithrombin or platelet factor 4.
J Biol Chem. 1982;257:400–406.
221. Boneu B, Caranobe C, Cadroy Y, et al. Pharmacokinetic studies of standard unfractionated heparin and low molecular weight heparins in the rabbit. Semin Thromb Hemost. 1988;14:18–27.[Medline] [Order article via Infotrieve]
222. Caranobe C, Barret A, Gabaig AM, et al. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of low molecular weight heparin (CY216) in normal and nephrectomized rabbits. Thromb Res. 1985;40:129–133.[Medline] [Order article via Infotrieve]
223. Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost. 1987;58:932–935.[Medline] [Order article via Infotrieve]
224. Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun. 1983;116:492–499.[Medline] [Order article via Infotrieve]
225. Pezzuoli G, Neri Serneri GG, Settembrini P, et al, and the STEP-Study Group. Prophylaxis of fatal pulmonary embolism in general surgery using low molecular weight heparin CY216: a multicenter, double-blind, randomized, controlled clinical trial versus placebo. Int Surg. 1989;74:205–210.[Medline] [Order article via Infotrieve]
226. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992;340:152–156.[Medline] [Order article via Infotrieve]
227. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery: a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost. 1992;67:417–423.[Medline] [Order article via Infotrieve]
228. Turpie AGG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986;315:925–929.[Abstract]
229. Hoek JA, Nurmohamed MT, Hamelynck KJ, et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost. 1992;67:28–32.[Medline] [Order article via Infotrieve]
230. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991;114:545–551.
231. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988;60:407–410.[Medline] [Order article via Infotrieve]
232. Eriksson BI, Kalebo P, Anthymyr BA, et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg. 1991;73A:484–493.
233. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomized comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991;303:543–548.
234. Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of low molecular weight heparin (Kabi 2165) versus adjusted dose subcutaneous standard heparin in the prophylaxis of deep vein thrombosis after elective hip surgery. Haemostasis. 1989;1:5–12.
235. Bergqvist D, Kettunen K, Fredin H, et al. Thromboprophylaxis in patients with hip fracture: a prospective, randomized, comparative study between Org 10172 and dextran 70. Surgery. 1991;109:617–622.[Medline] [Order article via Infotrieve]
236.
Borris LC,
Hauch O, Jorgensen LN, et al, for the Danish Enoxaparin Study Group.
Low-molecular-weight heparin (enoxaparin) vs dextran 70: the prevention
of postoperative deep vein thrombosis after total hip replacement.
Arch Intern Med. 1991;151:1621–1624.
237. Heit J, Kessler C, Mammen E, et al, for the RD Heparin Study Group. Efficacy of RD heparin (a LMWH) and warfarin for prevention of deep-vein thrombosis after hip or knee replacement. Blood. 1991;778:187A. Abstract.
238.
Anderson DR,
O’Brien BJ, Levine MN, et al. Efficacy and cost of
low-molecular-weight heparin compared with standard heparin for the
prevention of deep vein thrombosis after total hip arthroplasty.
Ann Intern Med. 1993;119:1105–1112.
239. Colwell CW, Spiro TE, Trowbridge AA, et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty: Enoxaparin Clinical Trial Group. Clin Orthop. 1995;321:19–27.
240. Fauno P, Suomalainen O, Rehnberg V, et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty: a comparison between unfractionated and low-molecular-weight heparin. J Bone Joint Surg Am. 1994;76A:1814–1818.
241. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg. 1994;76A:1174–1185.
242.
Spiro TE,
Johnson GJ, Christie MJ, and the Enoxaparin Clinical Trial Group.
Efficacy and safety of enoxaparin to prevent deep venous thrombosis
after hip replacement surgery. Ann Intern
Med. 1994;121:81–89.
243. Heit JA, Berkowitz SD, Bona R, for the Ardeparin Athroplasty Study Group. Efficacy and safety of low molecular weight heparin (Ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind dose-ranging study. Thromb Haemost. 1997;77:32–38.[Medline] [Order article via Infotrieve]
244. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993;19:1370–1376.
245.
Leclerc JR,
Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism
(VTE) after knee arthroplasty: a randomized double-blind trial
comparing enoxaparin with warfarin sodium.
Ann Intern Med. 1996;124:619–626.
246. Hamulyak K, Lensing AW, van der Meer J, et al, for the Fraxiparine Oral Anticoagulant Study Group. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Thromb Haemost. 1995;74:1428–1431.[Medline] [Order article via Infotrieve]
247.
Gent M, Hirsh
J, Ginsberg JS, et al. Low molecular weight heparinoid
Orgaran is more effective than aspirin in the prevention of venous
thromboembolism after surgery for hip fracture.
Circulation. 1996;93:80–84.
248.
Geerts WH, Code
KI, Jay RM, et al. A prospective study of venous thromboembolism after
major trauma. N Engl J
Med. 1994;331:1601–1606.
249.
Geerts WH, Jay
RM, Code KI, et al. A comparison of low-dose heparin with
low-molecular-weight heparin as prophylaxis against venous
thromboembolism after major trauma. N
Engl J Med. 1996;335:701–707.
250.
Agnelli G,
Piovella F, Buoncristiani P, et al. Enoxaparin plus compression
stockings compared with compression stockings alone in the prevention
of venous thromboembolism after elective neurosurgery.
N Engl J Med. 1998;339:80–85.
251. Prins MH, Den Ottolander GJH, Gelsema R, et al. Deep vein thrombosis prophylaxis with a low molecular weight heparin (Kabi 2165) in stroke patients. Thromb Haemost. 1987;58(suppl):117. Abstract.
252. Turpie AG, Levine MN, Hirsh J, et al. Double-blind randomized trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet. 1987;1:523–526.[Medline] [Order article via Infotrieve]
253. Green D, Lee MY, Lim AC, et al. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med. 1990;113:571–574.
254. Turpie AG, Gent M, Cote R, et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke: a randomized, double-blind study. Ann Intern Med. 1992;117:353–357.
255. Kuijer PMM, Prins MH, Buller HR. Low-molecular-weight heparins: treatment of venous thromboembolism. In: Sasahara AA, Loscalzo J, eds. Advances in Therapeutic Agents in Thrombosis and Thrombolysis. New York, NY: Marcel Dekker; 1997:129–147.
256.
Simonneau G,
Sors H, Charbonnier B, et al, for the THESEE Study Group. A comparison
of low-molecular-weight heparin with unfractionated heparin for acute
pulmonary embolism: the THESEE Study Group: Tinzaparine ou
Heparine Standard: Evaulations dans l’Embolic
Pulmonaire. N Engl J
Med. 1997;337:663–669.
257.
Levine M, Gent
M, Hirsh J, et al. A comparison of low molecular weight heparin
administered primarily at home with unfractionated heparin administered
in the hospital for proximal deep-vein thrombosis.
N Engl J Med. 1996;334:677–681.
258.
Koopman MM,
Prandoni P, Piovella F, et al, and the TASMAN Study Group. Treatment of
venous thrombosis with intravenous unfractionated heparin
administered in the hospital as compared with subcutaneous
low-molecular-weight heparin administered at home.
N Engl J Med. 1996;334:682–687.
259.
The COLUMBUS
Investigators. Low-molecular-weight heparin in the treatment of
patients with venous thromboembolism.
N Engl J Med. 1997;337:657–662.
260.
Decousus H,
Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters
in the prevention of pulmonary embolism in patients with
proximal deep-vein thrombosis: Prevention du Risque d’Embolie
Pulmonaire par Interruption Cave Study Group.
N Engl J Med. 1998;338:409–415.
261. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975–982.[Abstract]
262. Charbonnier BA, Fiessinger JN, Banga JD, et al, for the FRAXODI Group. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. Thromb Haemost. 1998;79:897–901.[Medline] [Order article via Infotrieve]
263.
Merli G, Spiro
TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily
compared with intravenous unfractionated heparin for treatment of
venous thromboembolic disease. Ann Intern
Med. 2001;134:191–202.
264.
Patrono C,
Coller B, Dalen JE, et al. Platelet-active drugs: the relationships
among dose, effectiveness, and side effects.
Chest. 1998;114:470S–488S.
265. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 1995;26:313–318.[Abstract]
266. FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease: Fragmin during instability in Coronary Artery Disease (FRISC) Study Group. Lancet. 1996;347:561–568.[Medline] [Order article via Infotrieve]
267.
Klein W,
Buchwald A, Hillis S, et al. Comparison of low molecular weight heparin
with unfractionated heparin acutely and with placebo for 6 weeks in the
management of unstable coronary artery disease: Fragmin in
Unstable Coronary Artery Disease Study (FRIC).
Circulation. 1997;96:61–68.
268.
Cohen M, Demers
C, Gurfinkel EP, for the ESSENCE Trial. A comparison of
low-molecular-weight heparin with unfractionated heparin for unstable
coronary artery disease: Efficacy and Safety of Subcutaneous
Enoxaparin in Non-Q-wave Coronary Events Study Group.
N Engl J Med. 1997;337:447–452.
269. Cohen M, Demers C, Lelouer F, et al. One year follow up of the ESSENCE trial (enoxaparin versus heparin in unstable coronary artery disease). J Am Coll Cardiol. 1998;31:79A. Abstract.
270.
Antman EM,
McCabe CH, Gurfinkel EP, et al, for the TIMI-11B Investigators.
Enoxaparin prevents death and cardiac ischemic events in
unstable angina/non–Q-wave myocardial infarction: results of the
Thrombolysis In Myocardial Infarction (TIMI) 11B Trial.
Circulation. 1999;100:1593–1601.
271.
Antman EM,
Cohen M, Radley R, et al. Assessment of the treatment effect of
enoxaparin for unstable angina/non-Q myocardial infarction: the TIMI
11B-ESSENCE meta-analysis.
Circulation. 1999;100:1602–1608.
272.
The FRAXIS
Study Group. Comparison of two treatment durations (6 days and 14 days)
of a low molecular weight heparin with a 6-day treatment of
unfractionated heparin in the initial management of unstable angina or
non-Q-wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic
Syndrome). Eur Heart J.. 1999;20:1553–1562.
273. FRISC II Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study: Fragmin and Fast Revascularisation during InStability in Coronary artery disease. Lancet. 1999;354:701–707.[Medline] [Order article via Infotrieve]
274.
International,
randomized, controlled trial of lamifiban (a platelet
glycoprotein IIb/IIIa inhibitor), heparin, or
both in unstable angina: the PARAGON Investigators: Platelet
IIb/IIIa Antagonism for the Reduction of Acute coronary
syndrome events in a Global Organization Network.
Circulation. 1998;97:2386–2395.
275. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina: Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med. 1998;228:1498–1505.
276.
PURSUIT Trial
Investigators. Inhibition of platelet glycoprotein
IIb/IIIa with eptifibatide in patients with acute coronary
syndromes: the PURSUIT Trial Investigators: Platelet
Glycoprotein IIb/IIIa in Unstable Angina Receptor
Suppression Using Integrilin Therapy.
N Engl J Med. 1998;339:436–443.
277. Kontny F, Dale J, Abildgaard U, et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;39:962–969.
278. Glick A, Kornowski R, Michowich Y, et al. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol. 1996;77:1145–1148.[Medline] [Order article via Infotrieve]
279.
Frostfeldt G.
Low molecular weight heparin (dalteparin) as adjuvant treatment of
thrombolysis in acute myocardial infarction: a pilot
study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS
II). J Am Coll Cardiol. 1999;33:627–633.
280.
Hanke H,
Oberhoff M, Hanke S, et al. Inhibition of cellular proliferation after
experimental balloon angioplasty by low-molecular-weight heparin.
Circulation. 1992;85:1548–1556.
281.
Buchwald AB,
Unterberg C, Nebendahl K, et al. Low-molecular-weight heparin reduces
neointimal proliferation after coronary stent
implantation in hypercholesterolemic minipigs.
Circulation. 1992;86:531–537.
282.
Faxon DP, Spiro
TE, Minor S, et al. Low molecular weight heparin in prevention of
restenosis after angioplasty: results of the Enoxaparin in
Restenosis (ERA) Trial.
Circulation. 1994;90:908–914.
283.
Cairns JA, Gill
J, Morton B, et al, and the EMPAR Collaborators. Fish oils and
low-molecular-weight heparin for the reduction of restenosis
after percutaneous transluminal coronary
angioplasty. Circulation. 1996;94:1553–1560.
284. Berge E, Abdelnoor M, Nakstad PH, et al, and the HAEST Study Group. Heparin in Acute Embolic Stroke Trial: low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. Lancet. 2000;355:1205–1210.[Medline] [Order article via Infotrieve]
285.
Roijer A,
Eskilsson J, Olsson B. Transoesophageal
echocardiography-guided cardioversion of atrial
fibrillation or flutter: selection of a low-risk group for immediate
cardioversion. Eur Heart J. 2000;21:837–847.
This article has been cited by other articles:
 |
|
 |
|
  S. Manzano-Fernandez, F. Marin, F. J. Pastor-Perez, C. Caro, F. Cambronero, J. Lacunza, E. Pinar, D. A. Pascual-Figal, M. Valdes, and G. Y. H. Lip Impact of Chronic Kidney Disease on Major Bleeding Complications and Mortality in Patients With Indication for Oral Anticoagulation Undergoing Coronary Stenting Chest, April 1, 2009; 135(4): 983 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Eikelboom and J. I. Weitz Anticoagulation for ST-Segment Elevation Myocardial Infarction Circulation, March 10, 2009; 119(9): 1186 - 1188. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dickneite, B. Doerr, and F. Kaspereit Characterization of the Coagulation Deficit in Porcine Dilutional Coagulopathy and Substitution with a Prothrombin Complex Concentrate Anesth. Analg., April 1, 2008; 106(4): 1070 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Al-Ansari, H.-k. Du, L. Yu, C. D. Ochoa, H. G. Garg, D. A. Quinn, and C. A. Hales Low-Molecular-Weight Heparin Inhibits Hypoxic Pulmonary Hypertension and Vascular Remodeling in Guinea Pigs Chest, December 1, 2007; 132(6): 1898 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Nikolsky, R. Mehran, G. Dangas, M. Fahy, Y. Na, S. J. Pocock, A. M. Lincoff, and G. W. Stone Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach Eur. Heart J., August 2, 2007; 28(16): 1936 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Luo, V. Zderic, F. A. Mann, and S. Vaezy Color and Pulsed Doppler Sonography for Arterial Bleeding Detection J. Ultrasound Med., August 1, 2007; 26(8): 1019 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. P. Jeske, M. K. McDonald, D. A. Hoppensteadt, E. C. Bau, A. Mendes, C. P. Dietrich, J. M. Walenga, and E. Coyne Isolation and Characterization of Heparin From Tuna Skins Clinical and Applied Thrombosis/Hemostasis, April 1, 2007; 13(2): 137 - 145. [Abstract] [PDF]
|
|
|
|
 |
|
 C. M. Dyke, N. G. Smedira, A. Koster, S. Aronson, H. L. McCarthy II, R. Kirshner, A. M. Lincoff, and B. D. Spiess A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 533 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hasan, S. D. Shnyder, A. R. Clamp, A. T. McGown, R. Bicknell, M. Presta, M. Bibby, J. Double, S. Craig, D. Leeming, et al. Heparin Octasaccharides Inhibit Angiogenesis In vivo Clin. Cancer Res., November 15, 2005; 11(22): 8172 - 8179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kucher, R. Quiroz, S. McKean, A. A Sasahara, and S. Z Goldhaber Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism Vascular Medicine, November 1, 2005; 10(4): 251 - 256. [Abstract] [PDF]
|
|
|
|
|
|
B. K. Nallamothu, E. R. Bates, J. S. Hochman, C. B. Granger, V. Guetta, R. G. Wilcox, H. D. White, P. W. Armstrong, S. Savonitto, G. Jia, et al. Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial Eur. Heart J., August 1, 2005; 26(15): 1506 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.S. Avidan, J.H. Levy, H. van Aken, R.O. Feneck, R.D. Latimer, E. Ott, E. Martin, D.E. Birnbaum, L.J. Bonfiglio, D.K. Kajdasz, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lansky, J. S. Hochman, P. A. Ward, G. S. Mintz, R. Fabunmi, P. B. Berger, G. New, C. L. Grines, C. G. Pietras, M. J. Kern, et al. Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women: A Statement for Healthcare Professionals From the American Heart Association Circulation, February 22, 2005; 111(7): 940 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Z. Goldhaber and U. J. Schoepf Pulmonary Embolism After Coronary Artery Bypass Grafting Circulation, June 8, 2004; 109(22): 2712 - 2715. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Shapiro Treating Thrombosis in the 21st Century N. Engl. J. Med., October 30, 2003; 349(18): 1762 - 1764. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Pravinkumar and N. R. Webster HIT/HITT and alternative anticoagulation: current concepts Br. J. Anaesth., May 1, 2003; 90(5): 676 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Niccoli and A P Banning Heparin dose during percutaneous coronary intervention: how low dare we go? Heart, October 1, 2002; 88(4): 331 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Reddan and P. S. Klassen Chronic Kidney Disease and Cardiovascular Risk: Time to Focus on Therapy J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2415 - 2416. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mureebe and D. Silver Heparin-Induced Thrombocytopenia: Pathophysiology and Management Vascular and Endovascular Surgery, May 1, 2002; 36(3): 163 - 170. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||